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Cell proliferation and differentiation are coordinated by synchronized patterns of 
gene expression.  The regulation of these patterns is achieved, in part, through 
epigenetic mechanisms that affect the nature of DNA packaging into chromatin.  
Specifically, post-translational modifications to histone tails impact the structural 
dynamics of nucleosomes, thereby affecting DNA accessibility to transcriptional 
complexes.  Accumulating evidence suggests that transcriptional regulators 
facilitate these alterations, resulting in altered local gene transcription.  Thus, the 
structural interpretations of histone modifications are responsible for the 
establishment and maintenance of discrete programs of gene expression that 
ultimately correspond with distinct biological outcomes.   
 Most histone lysine methyltransferases catalyze methyl transfer by way of 
the SET domain, a module encoded within many proteins that regulate diverse 
processes, including some critical for development and proper progression of the 
 vi
cell cycle.  One such group of proteins, the SET and MYND domain (Smyd) 
family have been demonstrated to be direct regulators of tumorigenesis and 
essential developmental processes.  Presented here is a functional 
characterization of two members of that family, Smyd2 and Smyd3.   
 Smyd2 is identified as a member of the Smyd family and reported here to 
possess SET-dependent histone H3, lysine 36-specific methyltransferase 
activity. Smyd2 specifically associates with the Sin3A histone deacetylase 
complex, suggesting a link between two independent chromatin modification 
activities. Finally, over-expression of Smyd2 in fibroblasts is shown to 
significantly suppress their rate of growth.  It is therefore proposed that Smyd2-
mediated chromatin modifications regulate specific gene expression, thereby 
having important implications for normal and neoplastic cell proliferation. 
 Aberrant expression of the histone H3-lysine 4-specific 
methyltransferase, Smyd3, has been implicated in colorectal, hepatocellular, and 
breast cell carcinogenesis.   Here, Smyd3 is also shown to target histone H4, 
lysine 20 (H4K20). However, over-expression of Smyd3 in fibroblasts results in 
global reduction of trimethylation at H4K20 and this is accompanied by a striking 
increase in cell proliferation.  As the methylation of H3K4 and H4K20 are 
normally associated with conflicting biological functions, I predict that these 
differential activities of Smyd3 are manifest under spatially and/or temporally 
distinct conditions, in the presence of different associating complexes, thereby 
resulting in effects that may be antagonistic of one another.  
 vii
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 From regulated gene expression to mitosis, chromatin acts as a 
structurally flexible repository of the genome [1].  In this manifestation, an entire 
chromosome is sequentially compacted through a series of highly ordered 
packaging while distinct regions of DNA are selectively made accessible to 
transcriptional complexes.  Thus, chromatin maintains a dynamic architecture 
that allows approximately 2 m of DNA to be parceled in the nucleus while 
retaining a remarkable degree of functionality (Fig. 1.1) [2, 3].  
At its foundation, chromatin is grounded in a succession of nucleosomes, 
the basic structural units [4], consisting of 146 base pairs of DNA, wrapped 1.7 
times around an octamer of core histones and separated by a linker region of 
approximately 50 base pairs.  The primary histones involved in the assembly of a 
nucleosome are histones H2A, H2B, H3 and H4.  These histones ultimately form 
octamers, such that each is represented twice in the nucleosome core unit [5]. 
The structure of each histone is highly conserved, including a folded core 
and an unstructured tail [6].  The histone core is a globular domain, forming a 
helix-turn-helix motif, which facilitates dimerization.  Conversely, the tails of 
histones do not adopt defined conformations, as demonstrated in x-ray 
crystallographic studies, except when bound to their cognate proteins [6].  These 
tail domains contain a number of conserved amino acid residues including lysine, 
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arginine, and serine [7].  Histone tails, which sustain a basic charge, can interact 
with the poly-anionic backbone of the core DNA, marginally contributing to 
nucleosomal stability [8].  Therefore, regulation of chromatin structure and 
transcription is often mediated through post-translational modifications that alter 
specific residues along these tails.  These modifications can affect the 
accessibility of nuclear factors to DNA or induce the recruitment of such factors 
to transcriptional or chromatin assembly pathways [9]. 
Histone-DNA interactions are formed primarily by rigid hydrogen bonds 
between the histone main chain amide and the phosphate oxygen of the DNA.  
These are strengthened by electrostatic interactions between basic side chains 
and negatively charged phosphate groups and other nonpolar interactions [10].  
While this allows, in theory, nucleosome formation on any DNA sequence, there 
may be specific sequence preferences for nucleosomal positioning [11].  The 
nature of the underlying DNA sequences, by which the histone core is wrapped, 
is likely the major determinant of the core histone displacement and the dynamic 
behavior of the nucleosome under the influence of the SWI/SNF ATPase and 
sequence-specific transcription factors [12].  The most thoroughly characterized 
nucleosomal assembly is the 30nm fiber, which is stabilized by linker histones 
[13-15] and the relative positioning of each nucleosome [16], ensuring intimate 
physical proximity while producing minimal internucleosomal attraction energy 
[17, 18].  Thus, this structure allows dramatic changes in the degree of 
compaction to occur without a concomitant change in topology.   
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Chromatin is manifest in a number of additionally heightened states of 
compaction [19], and even higher order structures occur upon interaction with 
non-histone, architectural proteins [20].  In the past three decades, a number of 
chromatin-related events including DNA methylation, incorporation of histone 
variants, post-translational modifications of histones, and ATP-dependent 
chromatin remodeling have been intensely studied.    These modifications, and 
the protein complexes involved with their facilitation, have been linked to the 
regulation of many biological processes dependent upon the accessibility of 
chromatin [21-24].  These include gene expression, DNA repair, chromosome 
segregation during mitosis, X chromosome inactivation, and chromatin 
condensation during apoptosis [25-28].   
Chromatin modifications impart epigenetic control of gene expression 
without requisite changes in DNA sequence.   Disrupting the balance of 
epigenetic networks has been linked to severe pathological consequences, 
including tumorigenesis, syndromes involving chromosomal instability, and 
neurological disorders [29-31].  Recent advances in our understanding of 
chromatin structure/regulation and epigenetic inheritance have led to the 
development of promising new therapies that target the enzymes and complexes 





1.12 DNA accessibility in transcriptional regulation 
The structure of heterochromatin restricts physical access of nuclear 
factors to the underlying DNA [33].  Regulation of chromatin architecture is, 
therefore, necessary but not sufficient for controlling gene expression.  The 
involvement of sequence-specific activators, repressors, mediator complexes, 
and general transcription factors are also required to manage transcriptional 
regulation [34, 35].  During transcriptional activation, the binding of gene-specific 
factors to defined DNA sequences triggers a cascade of spatially and temporally 
coordinated reactions.  These result in a chromatin template, appropriately 
remodeled, which enhances the binding of ubiquitous transcription factors and 
the general transcription machinery [36, 37]. 
Transcription factors interact with specific sequences and are divided into 
three classifications.  General transcription factors are subunits of the RNA 
Polymerase II complex, which transcribes template DNA into messenger RNA 
[38].  The upstream regulatory transcription factors recognize consensus 
elements located in promoter regions and act by increasing the efficiency of 
transcription initiation. General transcription factors and upstream transcription 
factors are ubiquitous factors that require accessible chromatin structure for DNA 
binding [38].  This is accomplished by the third group of transcription factors 
which induce the structural remodeling required to open distinct regions of 
chromatin.  These inducible factors are gene-specific and are synthesized or 
activated at discrete times and in distinct tissues.  For example, nuclear 
receptors, which constitute a large family of ligand-inducible transcription factors, 
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have the capacity to bind to condensed chromatin templates [39].  The response 
of a given receptor to a particular ligand depends on the set of co-regulators with 
which it is able to interact.  Recruited co-regulators are able to covalently modify 
histones or remodel nucleosomes in an ATP-dependent manner and these 
alterations modulate the promoter accessibility to both common transcription 
factors as well as the basal transcriptional machinery [40].  Ultimately, 
transcriptional activation results from the integration of specific and ubiquitous 
factor-binding at the promoter, suggesting that the constitution of the promoter is 
of critical importance [41].  
 
1.13 ATP-dependent nucleosome remodeling 
 Nucleosomal remodeling is an ATP-dependent process that alters 
chromatin structure in a non-covalent manner [42]. The complexes that facilitate 
this process are of fundamental importance because they affect the accessibility 
of DNA to other complexes involved in transcription, DNA repair, and replication.  
Thus, ATP-dependent chromatin remodeling can affect gene expression, cell 
cycle progression, and cell differentiation [43].  Chromatin remodeling complexes 
are divided into several classes, based on variation within their catalytic ATPase 
subunits.  Although these subunits display homology within the ATPase domain, 
additional domains vary significantly among classes.  For example, the SWI/SNF 
family contains a bromo domain [44], the ISWI family contains a SANT domain 
[45], and the Mi-2/NURD family, a chromo domain [46].  Each ATPase 
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associates with different subunits to form distinct multiprotein complexes and 
each subunit may be differentially involved in the regulation or targeting of 
remodeling activity (Fig. 1.2) [47].   
 Nagaich and colleagues studied the interaction between the glucocorticoid 
receptor (GR) and an array of nucleosomes, assembled on the mouse mammary 
tumor virus long terminal repeat.  They observed that receptor binding to 
nucleosomal DNA is enhanced by SWI/SNF and is accompanied by sequential 
reorganization of histone proteins within the nucleosomes.  The action of 
SWI/SNF is proposed to lead to changes in the position of histone H2B within the 
nucleosome in concert with the recruitment of GR to a new binding site within the 
nucleosomal DNA [48].  Recent advances have allowed nucleosome dynamics 
on promoters to be studied in real time and support the idea that individual 
nucleosomes may have an inherent capacity to ‘breathe’ [49].  
 
1.14 DNA methylation 
 Methylation of DNA is a covalent modification that occurs at cytosines 
within CpG-rich regions of DNA and is catalyzed by DNA methyltransferases 
[50].  The methylation of DNA affects the binding of proteins to their cognate 
DNA sequences [51].  Such addition of methyl groups can prevent the binding of 
basal transcriptional machinery and ubiquitous transcription factors [52].  In this 
way, DNA methylation contributes to epigenetic inheritance, allele-specific 
expression, inactivation of the X chromosome, genomic stability and embryonic 
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development [53].  Progressive DNA methylation is widely implicated as an agent 
of normal senescence as well as tumorigenesis [54].   
The majority of methylated CpG islands are located within repetitive 
elements including centromeric repeats, satellite sequences, and gene 
duplications.  These CpG regions are often found at the 5´ end of genes where 
DNA methylation affects transcription by recruiting methyl-CpG binding domain 
(MBD) proteins that function as adaptors between methylated DNA and 
chromatin-modifying enzymes [55]. There is a clear relationship between DNA 
methylation and other silencing mechanisms including histone modifications and 
chromatin remodeling [56, 57].  In fact, several studies suggest that DNA 
methylation is targeted specifically toward genes that are already suppressed by 
other mechanisms [54].  
 
1.15 Histone modifications 
 Histone tail alterations encompass the greatest range of variation in 
epigenetic regulation, encompassing more than 50 known sites of modification 
[58].  Histones are subject to several forms of post-translational modification, 
including methylation, citrullination, acetylation, phosphorylation, SUMOylation 
and ADP-ribosylation (Fig. 1.3) [7, 59].  These modifications impart biological 
consequences by acting as marks for the specific recruitment of regulatory 
complexes and affecting the structure of the nucleosome.  Acting in concert, the 
combination of different histone modifications is thought to constitute a “histone 
code” that is interpreted in the form of specific nuclear events [60, 61]. 
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Although the interplay among various histone modifications is still largely 
nebulous, a paradigm is rapidly emerging whereby methylation, acetylation, or 
phosphorylation at independent sites may work in tandem with other such 
modifications to convey unique biological consequences [62].  Such crosstalk 
has already been clearly demonstrated by a number of findings including the 
cooperation between acetylation and phosphorylation of histone H3 during the 
cell cycle [63],  the correlation between acetylation and arginine methylation in 
the regulation of estrogen-responsive genes [64], and the competition between 
methylation and acetylation of histone H3, lysine 9 toward the establishment  or 
disruption of heterochromatin [65].  As new studies continue to highlight the 
importance of crosstalk in epigenetic regulation, our early understanding of 
singular histone modifications have yielded to a more delicate model in which 
minor variations in broad patterns of modifications impart distinct outcomes.   
In 1964, Allfrey and colleagues noted a correlation between increased 
histone acetylation and augmented transcription [66].  Since then, much has 
been uncovered regarding the affects of histone acetylation.  This modification 
has been implicated in DNA replication, DNA repair, and modulation of chromatin 
structure [67].  Hyper-acetylation of histone lysine residues is thought to influence 
transcriptional activity by neutralizing the positive charge of the histone tails and 
decreasing their affinity for negatively charged DNA, thereby allowing access of 
transcription factors to promoters [68-70].  Conversely, histone deacetylation is 
believed to hinder the accessibility of DNA by restoring the net positive charge 
[71].  In addition to charge-neutralization, more recent studies indicate that 
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histone acetylation/deacetylation regulates transcription by altering higher-order 
folding properties of the chromatin fiber and providing specific binding surfaces 
for the recruitment of transcription co-regulators [69].   
Near promoter sites, acetylation of histone amino-termini provides binding 
surfaces for transcription factors of the TFIID transcription initiation complex as 
well as for proteins in chromatin-remodeling complexes [72]. Agalioti and 
colleagues have shown progressive acetylation of the human interferon (IFN)-β 
gene upon transcriptional activation.  Each acetylation pattern correlated with the 
recruitment of a specific protein.  The general transcription factors GCN5 and 
TAFII250, the largest subunit of the TFIID complex, are recruited to target 
promoter regions and sequentially acetylate H4 lysine 8 and H3 lysine 9 and 14, 
respectively.  In turn, H4 lysine 8 acetylation provides a binding site for BRG1 
that is part of the SWI/SNF complex that promotes ATP-dependent nucleosome 
remodeling [72].  In addition to affecting chromatin dynamics through alteration of 
histone tails, recent studies indicate that acetylation of lysines at the edge of the 
histone globular domain is also possible and this modification facilitates the 
recruitment of chromatin remodeling complexes in yeast [73].   
The first cloned histone acetyltransferase (HAT) was obtained from 
Tetrahymena thermophilia [74], and sequence similarity with previously identified 
transcription factors such as CBP/p300, TAFII250, and SRC-1, revealed that 
these transcriptional co-activators all possessed HAT activity [67, 75].  These 
findings strengthen the idea that local acetylation of histones by transcription 
factors contributes to the activation of promoter-specific gene expression.  
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Histone acetylases function in large complexes, such that associating subunits 
can modulate HAT activity and substrate specificity.  In addition, HAT activity can 
be affected by sequence-specific transcription factors as well as other histone 
modifications [76].  Homozygous deletions of distinct histone acetylases, in vivo, 
are manifest by disparate developmental defects, suggesting a highly specialized 
functionality for these enzymes [77].    
Antagonism of HAT activity is achieved by a group of enzymes called 
histone deacetylases (HDACs).  Traditionally, these are thought to impart 
transcriptional repression by catalyzing the removal of the acetyl moiety from 
histone lysines  [76].  The first mammalian HDAC identified is related to the yeast 
transcriptional regulator, Rpd3 [78].  Since then, additional HDACs have been 
discovered and parceled into subclasses, based on sequence homology with 
their yeast homologs.  The human class I histone deacetylases, similar to Rpd3, 
include HDACs 1, 2, 3 and 8.  A second class, including HDACs 4, 5, 6, 7, 9 and 
10, are similar to the yeast Hda1 and are regulated through subcellular 
localization.  Class III HDACs,  also referred to as the sirtuins, exhibit significant 
sequence and functional divergence from the class I and II groups [71].  This 
third class of HDACs displays NAD-dependent deacetylase activity, similar to the 
yeast Sir2 protein, and play an essential role in epigenetic silencing [79].  
Uniquely, class III HDACs are not sensitive to traditional HDAC inhibitors such as 
trichostatin A or valproic acid.  Although the substrate specificity of distinct 
HDACs remains ill-defined, phylogenetic analyses reveal that HDACs evolved in 
the absence of histone proteins, suggesting that primary HDAC substrates may 
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not be histones [76].  In addition to its classic role, invoking transcriptional 
repression, contemporary studies have revealed that deacetylation is also 
required at the promoters of many transcriptionally active genes [80].  Thus, 
histone deacetylation is an excellent example of the paradoxical complexities of 
the histone code.     
While acetylation of histone tails is largely ephemeral in nature, histone 
methylation is widely observed to be a mark that confers long-standing 
epigenetic memory [81]. Mounting evidence suggests that histone lysine 
methylation is a critical factor in such pathways as transcriptional regulation, X 
chromosome inactivation, DNA methylation, and the formation of 
heterochromatin  [25-27].  Catalyzed by histone methyltransferases, this 
modification ultimately mediates either gene activation or silencing, in a residue-
dependent manner [81].  The level of specificity is heightened by the variation in 
biological consequences associated with whether a residue is mono-, di-, or tri-
methylated [82, 83].  It has also been reported that many transient histone 
modifications work in tandem with histone lysine methylation, further increasing 
the potential complexity of this epigenetic modification [1].  
Most histone lysine methyltransferases catalyze methyl transfer by way of 
the SET domain, a module encoded within many proteins that regulate diverse 
processes, including some critical for development and proper progression of the 
cell cycle [27, 60, 84].  Residue-specific histone lysine methylation typically 
correlates with distinct states of gene expression [85].  Most of the known 
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targeted lysines of histone methyltransferases occur on histone H3 which thereby 
serves as a conduit of epigenetic regulation.  In general, lysine methylation at 
histone H3, lysine 9 (H3K9), H3K27, or H4K20 corresponds with gene silencing, 
whereas methylation of H3K4, H3K36, or H3K79 is associated with actively 
transcribed genes.  However these paradigms are far too narrow to encompass 
the growing intricacies of the histone code [85].  Recent evidence implicates 
histone methylation in the recruitment of chromatin remodeling complexes, as is 
the case with CHD1, an ATP-dependent chromatin remodeling factor that 
specifically binds methylated H3K4 [86].  Once thought to be a permanent 
modification, enzymes have now been identified that are capable of reversing 
histone methylation at specific sites [81, 87].  
The incorporation of histone variants provides yet another echelon to the 
capacity of epigenetic mechanisms to store cellular information  [28].  Locally, 
this affects nucleosome structure as well as the propensity of variant-containing 
chromatin to be remodeled.  Hence, histone variant incorporation can alter 
nucleosome stability, mobility, and potential patterns of histone modifications, 
likely affecting higher order structure and downstream events [88-90].  For 
example, a specialized H3-like variant CENP-A, replaces H3 in centromeric 
nucleosomes to maintain a unique structure that is critical for proper 
chromosomal segregation [91].  There are many present studies emphasizing the 
physiological relevance of histone variants and their growing role in our 
understanding of epigenetic regulation [28].  
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1.16 Non-coding RNA 
Accumulating evidence suggests the existence of RNA regulatory 
networks that are involved in the regulation of gene expression at various levels 
[92].  It has been observed that non-coding RNA, targeting CpG islands in 
promoter regions, acts in concert with both DNA and histone methylation to affect 
gene transcription [93-95].  In fission yeast and in Drosophila, the involvement of 
small interfering RNA has been studied  in sequence-specific targeting of 
transgenes, transposable elements, heterochromatin, and some cases of 
polycomb-mediated gene silencing [96].  Although the current understanding of 
the influence of non-coding RNA on transcriptional activity is still incomplete, this 
is an exciting new front in the field of epigenetic modifications that promises to 
possess answers to broader questions on transcriptional regulation [97]. 
 
1.2 Smyd Family Significance 
 The development of tissues and organisms depends upon the acquisition 
of distinct programs for gene expression among individual cell types [98].  These 
programs are maintained in a heritable state by epigenetic mechanisms that 
impart cellular memory [99].  In this way, the global synchronization of patterns in 
gene expression broadly dictates developmental consequences [100].  At the 
core of such gene regulation are mechanistic pathways that affect the packaging 
of DNA into chromatin, thereby establishing the degree of DNA accessibility to 
transcriptional complexes [58, 60, 100, 101].  These pathways are highlighted in 
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preceding sections and include DNA methylation, chromatin remodeling, histone 
replacement, and alterations to histone tails [60, 102, 103].     
 As described in section 1.15, most histone lysine methylation is catalyzed 
by proteins containing a SET domain [27, 60].  The SET and MYND (Smyd) 
family comprises a subset of five SET domain-containing proteins that have 
unique domain architecture.  Specifically, this family of proteins is defined by a 
SET domain that is split into two segments by a MYND domain, followed by a 
cysteine-rich post-SET domain [104].  Members of this family may be important 
in developmental regulation, as targeted disruption of the Smyd1 gene results in 
impaired cardiomyocyte maturation, flawed cardiac morphogenesis, and 
embryonic lethality (Fig. 1.4) [104].  Functionally, Smyd1 is thought to regulate 
gene expression via its association with histone deacetylase activity [104] and 
the muscle-specific transcription factor, skNAC [104, 105].  Recent evidence 
demonstrates that skNAC is methylated by Smyd1 (personal communication 
from Dr. Li Zhu). 
 Pathological consequences have also been associated with aberrant 
expression of Smyd proteins in mature tissues.  Smyd3 has been noted for its 
involvement in cancer cell proliferation, underscoring the importance of proper 
regulation of the Smyd family members.  Smyd3 is over-expressed in most 
hepatocellular and colorectal carcinomas, and its exogenous over-expression in 
fibroblasts significantly augments growth.  Functionally, Smyd3 has been shown 
to have an active SET domain that modulates chromatin structure through its 
intrinsic H3K4-specific histone lysine methyltransferase (HKMT) activity.  The 
 14
enhancement of cell growth that is associated with over-expression of Smyd3 is 
completely abolished when the SET domain is mutated. [106].  Further 
investigation of the activity and specificity of the SET domain in other Smyd 
proteins is critical for our understanding of the broader functional and biological 
potential of this family. 
 The MYND domain of Smyd proteins encompasses a putative zinc-finger 
motif that facilitates protein-protein interactions.  This domain is present in 
several other transcriptional regulators where it is known to contribute in 
developmental processes [107, 108].   Interface at the MYND domain occurs 
through a PXLXP motif in the associating protein.  For example, the associations 
of Smyd1B with HDACs and the transcription factor, skNAC, are mediated 










Figure 1.1:  Chromatin condensation.  The basic structural unit of chromatin is 
the nucleosome, in which double-helical DNA wraps around an octamer of core 
histones.  Each unit is connected to the next nucleosome by a short sequence of 
linker DNA.  This ‘beads on a string’ architecture is further condensed into the ‘30 
nm fibre.’  Chromatin is packed additionally into higher-order structures, allowing 
approximately 2 meters of cellular DNA to be parceled in the nucleus. (Adapted 






Figure 1.2: Remodeling chromatin.  Chromatin-remodeling is required for 
transcriptional activation. (A) At the gene promoter, Swi5p recruits the 
SWI/SNF and HAT chromatin-remodeling complexes to initiate transcription.  
SWI/SNF and the HAT complex cooperatively facilitate binding of gene-specific 
activators such as SBF. (B) Upstream activating elements (blue and green) 
facilitate the recruitment of HATs during assembly of the RNA polymerase II 
(RNAPII) pre-initiation complex. Histone acetylation recruits the SWI/SNF 
complex, which further disrupts the structure of the promoter-bound 
nucleosome. This permits TBP binding to the TATA element, and completes 








Figure 1.3: Common sites of histone modifications.  Histone tail alterations 
encompass the greatest range of variation in epigenetic regulation.  Shown here 
schematically, N-terminal tails project from within the histone core of chromatin.  
Numbers correspond to specific residues of the associated tails that are known to 
be the targets of a variety of post-translational modifications.  These alterations 
impact the degree of chromatin condensation which, in turn, regulates 




Figure 1.4 Targeted deletion of Smyd1 (Bop) results in embryonic lethality 
due to cardiac enlargement.  Left and right lateral views of wildtype (WT; a,b) 
and Smyd mutant (c,d) embryos at E9.5 are shown. Gross analysis of mutant 
embryos shows growth retardation, an enlarged ventricular chamber (v) and a 
single ventricular segment, in contrast to wildtype embryos. Scale bars, 400 m. 
a, atria; h, head; lv, left ventricle; ot, outflow tract; rv, right ventricle.  (Adapted 





2. MATERIALS AND METHODS 
2.1 Computational analysis 
 The Smyd family members were identified from BLAST comparisons using 
the protein databases found at the National Center for Biotechnology Information 
(NCBI) web site (http://www.ncbi.nlm.nih.gov/). The ClustalW and BOXSHADE 
programs were used for alignments and shading of Smyd family proteins 
 
2.2 Cell culture 
 Cells lines were grown in DMEM, supplemented with 10% fetal bovine 
serum, 1 mM L-glutamine, 1% non-essential amino acids, penicillin, 
streptomycin, and fungizone (all from Life Technologies), at 37° C in a humidified 
atmosphere of 5% CO2.  293T, 10T1/2, HeLa, and NIH3T3 cells, obtained from 
ATCC, were used in these studies.   
 
2.3 Constructs   
 The SV40-luciferase reporter, containing five copies of the GAL4-UAS, 
was obtained from J. Milbrandt [109].  pRL-TK was purchased from Promega.  
The GAL4-mammalian expression construct, GAL4-DBD (DNA-binding domain), 
has been described previously [104].  The Smyd2 and Smyd3 full-length EST 
clones were obtained from Invitrogen.  The GAL4-Smyd2 mammalian expression 
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vector was constructed by PCR amplification (5’ ATG CGC GCC GAG GCC 
CGC; 3’ TCA GTG GCT CTC AAT CTC CTG) and restriction digestion (Not I; 
Xba I) followed by subcloning into the GAL4-DBD plasmid [104].  The Myc-
Y240F and Myc-Y239F point mutations were generated within the SET domain of 
Myc-Smyd2 (primers: 5’ CGA GGT GTT CAC CAG CTT CAT CGA CCT GCT 
ATA TCC; 3’ GGA TAT AGC AGG TCG ATG AAG CTG GTG AAC ACC TCG) 
and Myc-Smyd3 (primers: 5’ GGA GCT CAC CAT CTG CTT CCT GGA CAT 
GCT GAT GAC C; 3’ GGT CAT CAG CAT GTC CAG GAA GCA GAT GGT GAG 
CTC C), respectively, using the GeneEditor in vitro Site-Directed Mutagenesis 
System (Promega) according to the instructions of the manufacturer.  The FLAG-
tagged HDAC1-F mammalian expression plasmid was a kind gift from S.L. 
Schreiber [110].  The FLAG-tagged MBD3-F and MTA2-F expression plasmids 
were supplied by R.M. Evans [111].  HELZ, MICAL and FKBP38 were kind gifts 
from the laboratory of our collaborator, Dr. Deepak Srivastava [106, 112, 113].  
Frizzled 2 was provided by the laboratory of Dr. M. Sheng [114].  GST-Smyd3 
was constructed by PCR amplification using the Smyd3-GAL4 template (primers: 
5’ GGA TTC ATG GAG GCA CTG AAG GTG; 3’ GAA TTC TTA GGA GGC TCG 
TAT TTG GGC) and subcloning into pGEMT-EZ (Promega).  The resulting 
construct was digested with BamHI and EcoRI, followed by subcloning of the 
insert into pGEX-6P-1 (Promega).  The skNAC E34-GST construct was obtained 
by excision of E34 from the FLAG-E34 construct (previously described) [105] 
followed by subcloning of the fragment into pGEX-6P-1 (Promega).  The RNAPII 
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CTD expression construct used has been previously described [115].  The 
sequences of all constructs were confirmed by DNA sequencing.     
 
2.4 Transient transfections and luciferase assays 
 All transfections were performed using FuGENE6 reagent (Roche), 
according to the instructions of the manufacturer.  For immunoprecipitation 
experiments, 293T cells were plated at a density of 2 X 106 cells per 100 mm 
plate, 24 hours prior to transfection.  8 µg of total DNA plus 24 µl of FuGENE6 
reagent were used per 100 mm plate.  Cells were harvested 48 hours after 
transfection.  For luciferase reporter assays, 10T1/2 cells were seeded at a 
density of 2 X 105 cells per 6-well plate 24 hours prior to transfection.  3.5 µg of 
total DNA plus 10.5 µl of FuGENE6 reagent were used per well.  Luciferase 
assays were performed using the Dual-Luciferase Reporter Assay System kit 
(Promega) according to the manufacturer’s directions.  Samples were analyzed 
using a Dynex microtiter luminometer. 
 
2.5 Antibodies 
 The anti-Myc monoclonal (9E10), anti-HA monoclonal (H9658), and anti-
FLAG monoclonal (M2) antibodies were purchased from Sigma-Aldrich.  The 
anti-GAL4 mouse monoclonal (RK5C1) and the anti-Sin3A rabbit polyclonal (K-
20) antibodies were purchased from Santa Cruz Biotechnology.  Antibodies for 
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determining the specificity of HMT activity are detailed below.  The anti-RNA Pol 
II antibody (clone 8WG16) was obtained from UpState (Charlottesville, VA). 
Peroxidase-conjugated whole IgG secondary antibodies were purchased from 
Jackson ImmunoResearch Laboratories.   
 
2.6 Multiple tissue northern analysis 
 Northern blotting was performed using ULTRAhyb Hybridization Buffer 
(Ambion) according to the instructions of the manufacturer.  The probes for full-
length Smyd2 and Smyd3 were generated by restriction digest excision (Not I; 
Xba I) from their respective GAL4 mammalian expression constructs and the 
Strip-EZ DNA Probe Synthesis Kit (Ambion) as described in the manual.  The 
probe for full length Smyd1 was generated by restriction digest excision (EcoRI) 
from the pBK-CMV-Smyd1B expression construct described previously [105].  
The multiple tissue Northern blot was purchased from Ambion (FirstChoice 
Northern Blot Mouse Blot I).  Blots were detected using a phosphoimager. 
 
2.7 In situ hybridization 
 The DNA probe for full-length Smyd2 was generated by restriction digest 
excision (Not I; Xba I) from its above-described GAL4 mammalian expression 
construct.  Probe synthesis, hybridization, and autoradiography were performed 
as described in Lu et al. [116] with slight modifications.  Briefly, embryos were 
 23
obtained at day 13.5 post-coitus and fixed overnight in 4% paraformaldehyde.  
Hybridization of tissue sections with sense and antisense DNA probes was 
performed overnight at 55˚C, 7.5x105 cpm per slide.  Unhybridized probe was 
removed through stringent washing and slides were coated with K.5 nuclear 
emulsion (Ilford, UK) followed by exposure at 4˚C for 21 days.  Once developed, 
slides were counterstained with hematoxylin and observed by bright and dark 
field optics.   
 
2.8 Cellular localization by fluorescence imaging 
 293T cells were transfected with 1µg of plasmids, encoding myc tagged 
Smyd2, using Fugene 6 (Roche), according to the manufacturer’s instructions.  
48 hr post-transfection, cells were fixed (4% paraformaldehyde in PBS for 10 
min), washed, and permeabilized (0.5% Triton X-100 in PBS for 15 min).  
Monoclonal mouse anti-myc antibody was incubated 45 min at room 
temperature. After washing, goat anti-mouse Alexa 488 (Molecular Probes) was 
diluted 1:400 in 2% BSA and incubated 15 min at room temperature in the dark.  
Nuclei were counterstained with DAPI.  Slides were washed twice for 45 min and 
mounted with VectaStain.  Cells were analyzed by sequential confocal laser 




2.9 Cell proliferation assay   
 NIH3T3 cells were transfected with 6µg of Smyd1-Myc, Smyd2-Myc, 
Smyd3-Myc, or pcDNA3 alone.  The effects of the over-expression of each 
protein on cell growth were observed over a 6-day period and evaluated by cell 
counting using trypan-blue exclusion. 
 
2.10 In vitro histone methyltransferase assay 
 293T cells were transfected with plasmids expressing Myc-tagged 
wildtype Smyd2 (Smyd2-Myc), wildtype Smyd3 (Smyd3-Myc), mutant Smyd2 
(Smyd2 (Y240F)-Myc), or mutant Smyd3 (Smyd3 (Y239F)-Myc) and the over-
expressed, tagged proteins were purified by immunoprecipitation with an anti-
Myc antibody.  The histone methyltransferase assay was performed as described 
in Hammamoto et al. [106].  Briefly, the Smyd proteins were incubated with 1µg 
of mixed histones from calf thymus (Sigma) or recombinant H3 (Upstate).  In 
addition, 2µCi S-adenosyl-L –[methyl-3H ] methionine (SAM; Amersham 
Biosciences) was included as a methyl donor.  All reactions were carried out in 
40µl HMT reaction buffer (10mM dithiothreitol, 100mM NaCl, 4mM MgCl2, and 
50mM Tris-HCl at pH 8.8) at 30°C for 3 hours.  An 18% SDS-PAGE gel was used 
to resolve the samples and fluorography was used visualize positive methylation.  
Substrate loading was visualized by Coomassie blue staining.  
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 To determine the specificity of Smyd2 activity, immunoprecipitated Smyd 
proteins were incubated with recombinant H3 and 20µM unlabelled SAM (Sigma) 
in 40µl HMT reaction buffer at 30°C for 1 hour.  Western blot analysis was 
conducted using antibodies against   dimethylated H3K4,  trimethylated H3K4, 
dimethyl H3K9, trimethyl H3K9, trimethyl H3K27, dimethyl H3K36, or dimethyl 
H3K79 (all from Upstate, Charlottesville, VA).    
 Proximity bead HMT assays were conducted as follows:  2µCi of the 
methyl-donor S-adenosyl-L–[methyl-3H ] methionine (SAM; Amersham 
Biosciences) were incubated with .1µg of Smyd3 and .1µg of a Histone H3 
peptide, in which lysine 4 is mono-methylated (sequence of the peptide: acetyl-
RTKQTARKSTGGKAPRK-biotin).  The assay was carried out for three hours at 
30°C in 20µl HMT reaction buffer.  At the end of the incubation time, 100µl of 
binding buffer (1x PBS containing 1% NP-40 and 0.1% SDS) was added.  The 
substrate was then precipitated using 10µl of Streptavidin PVT SPA Scintillation 
Beads (Amersham Biosciences; used as 50% slurry in binding buffer) for one 
hour at room temperature on a rocking platform, followed by five washes in 
binding buffer and scintillation counting.   
 
2.11 Immunoprecipitations 
 Protein-A on Sepharose CL-4B was obtained from Sigma and 300mg 
were washed in 10ml low IPB buffer (150mM NaCl; 2mM EDTA; 0.5% NP-40; 
25mM Tris, pH7.5;) containing 10mg BSA.  The wash was carried out overnight 
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at 4°C while rotating. The protein-A beads were subsequently washed 2 times in 
10ml low IPB buffer, before being resuspended in 3ml low IPB. Protein G-PLUS 
Agarose was obtained from Santa Cruz Biotechnology.  293T cells were 
transiently transfected and later harvested, 48 hours after transfection.  Cells 
were collected and lysed in RIPA buffer (150mM NaCl, 1% NP-40, 0.5% DOC, 
50mM Tris pH 8, 0.1% SDS) containing protease inhibitors for 30 minutes on ice, 
followed by brief sonication. Protease inhibitor cocktail tablets (mini-complete; 
Roche Molecular Biochemicals, Indianapolis, IN) were included for all incubations 
and washes. Cells were centrifuged (16,000g) for 10 minutes at 4° C and 
supernatants were incubated with primary antibody (0.5 – 2ug/ml) on ice for one 
hour. Lysates were subsequently centrifuged at 4°C for 10 minutes and the 
supernatants were incubated with 25μl protein A-Sepharose/protein G PLUS-
agarose (25μl) at 4°C with rotation for 1 hour. Resulting immune complexes were 
washed 6 times with 1ml low IPB and immunoprecipitated proteins were 
resuspended in 40μl of 2X SDS loading buffer (20% glycerol, 250 mM Tris, pH 
6.8, 2%SDS, 200 mM β-mercaptoethanol, bromophenol blue to color), boiled for 
5 minutes, and resolved by 8-15% SDS-PAGE. 
 
2.12 Western blot analysis 
 After separation by SDS-PAGE, proteins were transferred to a 
nitrocellulose membrane (Protran BA, Schleicher and Schuell, NH) using 
electrophoretic transfer [117]. Membranes were blocked using 5% nonfat milk 
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(10g nonfat milk, 150 mM NaCl, 10 mM Tris pH 8, 0.05% Tween-20) overnight at 
4°C. Membranes were later incubated with 1° antibody for 1 hour at room 
temperature followed by washing in TBS-T (150mM NaCl, 20mM Tris pH 8, 0.1% 
Tween-20) four times for 15 minutes.  Membranes were then incubated with 2° 
antibodies for 1 hour at room temperature with and subsequently washed with 
TBS-T four times for 15 minutes. Blots were exposed and developed using the 
ECL blot detection reagent (Amersham Pharmacia Biotech) according to the 
instructions of the manufacturer. 
 
2.13 Cloning of the Smyd2 conditional targeting construct 
 To construct the Smyd2 conditional targeting construct, two genomic 
fragments were first subcloned from the C57BL/6 murine Bac clone-
RPC124288J3.  A 2.2kb KpnI fragment containing exon 1 and a KpnI fragment 
containing 5.2kb of intronic sequence between exons 1 and 2 was subcloned into 
pBluescript (Stratagene).  Fragment 1 (5.2kb) was excised with KpnI, blunt 
ended, and ligated into the unique blunt ended SalI site of pDELBOY [118].  The 
resulting clones were screened for correct orientation and for the regeneration of 
the SalI site.  Fragment 2 (2.2kb) was excised with KpnI and ligated into the 
unique KpnI site of pDELBOY containing fragment 1.  This was subsequently 
screened for correct orientation.  Fragment 3, containing 0.6kb upstream of exon 
1, was generated using Platinum Pfx DNA Polymerase (Invitrogen), C57BL/6 
genomic DNA as template, and the following primer pair: 
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5’GTCGACATTGAGCTAATGTGCTTA-3’; 
5’-CTCGAGGTAACACTCAACCTCTGC-3’.   
 The resulting PCR product was treated with TAQ Polymerase, ligated into 
pGEMTEASY (Promega), and excised with SalI and XhoI.  This product was 
ligated into the unique XhoI site of pDELBOY containing fragments 1 and 2 and 
subsequently screened for correct orientation.  The completed targeting construct 
was linearized at the short arm of homology using XhoI.  C57BL/6 ES cells were 
then transfected and selected with G418 and gancyclovir.  Targeted ES cell 
colonies were screened by Southern hybridization analysis using probes specific 
for the genomic sequence external to the arms of homology.  The 5’ Southern 
used a 0.8kb PCR fragment using the following primer pair: 
5’-GGCTGGAGTTAGAGGTGGTTATGA-3’; 
5’-ACAGCTCTGGGCTCGGAAATAAAG-3’.   




2.14 Acid histone extraction 
 Cells (4x107) were washed twice with ice-cold PBS and resuspended in 
Triton extraction buffer (TEB: PBS containing 0.5% Triton X (v/v), 2mM 
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phenylmethylsulfonyl fluoride, 0.2% NaN3 (v/v)).  Cells were lysed (H-Lysis 
solution: 0.25M sucrose, 3 mM CaCl2, 1 mM Tris pH8.0, 0.5% NP-40) on ice for 
10 minutes and subsequently centrifuged at 2000rpm for 10 minutes at 4°C.  The 
pellet was washed in half the volume of TEB and centrifuged as before.  The 
product was washed in wash solution (300 mM NaCl, 5mM MgCl2, 5mM DTT, 
0.5% NP-40) and centrifuged as before.  Acid extraction was conducted at 4° 
overnight in extraction buffer (0.5M HCl, 10% glycerol, 0.1M 2-
mercaptoethylamine-HCl).  Samples were centrifuged as before and protein 
concentration was determined by Bradford assay.   
 
 
2.15 Affinity selection mass spectrometry 
 Affinity selection–mass spectrometry (ASMS) was employed for screening 
pools of small molecules for their ability to interact with Smyd3.  Precise methods 
are detailed in [119].  Briefly, Smyd3 was incubated with known libraries of 
potentially interacting small molecules (incubation buffer included 50 mM Tris, pH 
7.5 with 5% DMSO).  The product was injected into a mobile phase of 50 mM 
NaH2PO4, pH 7.5, and complexes were separated from unbound components 
using size exclusion chromatography.  Small molecules were then dissociated 
from Smyd3 with 5% CH3CN/95% H2O in 0.2% formic acid and identified based 
on their known library of origin and mass spectrometry.   
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2.16 Hsp90PlusTM genotype 
F-hsdS gal omp T (λ cI857 ind-1 nin-5 Sam-7 lacUV5-T7 gene 1) Lon- . E. coli B 
strain with a λ prophage carrying the T7 RNA polymerase gene under the lacUV5 
promoter and a pACYC177-derived chloramphenicol-resistant plasmid 
expressing full-length human Hsp90α or Hsp90β.  These strains were obtained 
from Expression Technologies, Inc. and handled according to the instructions of 
the manufacturer.   
 
2.17 Expression and purification of soluble GST-fusion proteins  
GST-Smyd2, GST-Smyd3, and GST-RNAPII CTD were transformed into 
Plus90αTM, Plus90βTM (Expression Technologies, Inc., San Diego, CA), or 
standard BL-21 competent E. coli cells and selected according to the 
manufacturer’s instructions (www.exptec.com).  Transformants were inoculated 
into 10ml of LB broth, containing 150μg/ml ampicillin and cultures were left to 
shake at 37˚C overnight.  Overnight cultures were used to inoculate 250ml of LB 
broth, containing 150μg/ml ampicillin and cultures were incubated on a shaker at 
37˚C until OD600 reached 0.5.  At that time, 100mM IPTG was added to a final 
concentration of 0.1 mM and cultures were grown for an additional 5 hours at 
22˚C.  Cells were then pelleted at 5000 X g for 10 minutes, and 2.5g of wet cell 
paste was isolated from each culture pellet.  The isolated cell paste was 
resuspended and lysed at room temperature in 12.5ml of BugBuster HT 
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(Novagen) containing a protease inhibitor cocktail (Roche), according to the 
manufacturer’s instructions.  Lysis proceeded for 20 min. on a shaking platform 
followed by centrifugation at 10,000 X g for 10 min. at 4˚C.  The supernatant was 
transferred to a clean flask containing 25ml binding buffer (20mM Hepes [pH 
7.6], 100mM KCl, 20% glycerol, 1mM DTT, 1mM EDTA, and 1X protease 
inhibitor cocktail [Roche]) and 3.5ml 10% triton X-100.  To this, 1ml of a 50% 
slurry of glutathione agarose beads (Sigma-Aldrich), equilibrated with binding 
buffer, was added to the mixture and incubated on a rocking platform for 8 hours 
at 4˚C.  Beads were subsequently centrifuged at 2,000 X g and washed 6 times 
in 20ml binding buffer that contained no protease inhibitors.  Beads were then 
washed 4 times in PreScission (Amersham Bioscience) cleavage buffer 
(prepared as described in the manufacturer’s protocol) and GST- cleavage was 
accomplished using PreScission Protease (Amersham Bioscience) according to 
the manufacturer’s protocol.  Purity of the products was verified using silver 
staining of SDS-PAGE gels. 
 
2.18 Expression and purification of insoluble GST-fusion proteins    
Expression of insoluble GST-fusion proteins was performed as described above.  
For purification of insoluble GST-fusion proteins, the pellets obtained from the 
post-lysis centrifugation were resuspended in 12.5ml of BugBuster (Novagen).  
Lysozyme was added to a final concentration of 200μg/ml and the inclusion 
bodies were isolated according to the BugBuster protein extraction protocol 
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(Novagen).  GST-fusion proteins were treated using the Novagen Protein 
Refolding Kit, according to the directions of the manufacturer.  Refolded fusion 
proteins were purified on glutathione beads and the GST-moiety was 
subsequently cleaved, as described above. 
 
2.19 Smyd polyclonal antibody production 
 Smyd1 polyclonal antibodies were generated by immunizing New Zealand 
White rabbits four times each with 50µg Smyd1B-6XHis protein produced in 
insect cells and purified on a nickel column.  Rabbit serum was collected before 
immunization as a negative control.  The specificity of the Smyd1 antibody was 
tested by comparing its reactivity on western blots arrayed with lysates from 
293T cells over-expressing Smyd1B fusion proteins versus lysates of 293T cells 
over-expressing Smyd2 and Smyd3 fusion proteins.  At a dilution of 1:1000, the 
Smyd1 polyclonal antiserum was highly reactive against Smyd1 fusion proteins 
but completely inert toward Smyd2 and Smyd3 fusion proteins.   
 Smyd2 polyclonal antibodies were generated by immunizing New Zealand 
White rabbits four times each with 50µg Smyd2 protein produced in E. coli as 
GST-fusions and purified on a GST-column as detailed in 2.17.  The GST-moiety 
was cleaved as part of the purification process, as described in 2.17, prior to the 
injections.  Rabbit serum was collected before immunization as a negative 
control.  The specificity of Smyd2 antibody will be tested as described above.   
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 Smyd3 polyclonal antibodies were prepared as detailed above for Smyd1.  

















3. IDENTIFICATION AND CHARACTERIZATION OF SMYD2 
3.1 Abstract 
 Disrupting the balance of histone lysine methylation alters the expression 
of genes involved in tumorigenesis including proto-oncogenes and cell cycle 
regulators.  Methylation of lysine residues is commonly catalyzed by a family of 
proteins that contain the SET domain.  Here, I report the identification and 
characterization of the SET domain-containing protein, Smyd2. 
 Smyd2 mRNA is most highly expressed in heart and brain tissue, as 
demonstrated by northern analysis and in situ hybridization.  Over-expressed 
Smyd2 localizes to the cytoplasm and the nucleus in 293T cells.  Although 
accumulating evidence suggests that methylation of histone 3, lysine 36 (H3K36) 
is associated with actively transcribed genes, I show that the SET domain of 
Smyd2 mediates H3K36 dimethylation and that Smyd2 represses transcription 
from an SV40-luciferase reporter.  Smyd2 associates specifically with the Sin3A 
histone deacetylase complex, which was recently linked to H3K36 methylation 
within the coding regions of active genes in yeast. Finally, I report that 
exogenous expression of Smyd2 suppresses cell proliferation. 
 I propose that Sin3A-mediated deacetylation within the coding regions of 
active genes is directly linked to the histone methyltransferase activity of Smyd2.  
Moreover, Smyd2 appears to restrain cell proliferation, likely through direct 




 Cell proliferation and differentiation are coordinated by synchronized 
patterns of gene expression.  The regulation of these patterns is achieved, in 
part, through epigenetic mechanisms that affect the nature of DNA packaging 
into chromatin [98].  Specifically, post-translational covalent modifications to 
histone tails impact the structural dynamics of the nucleosome, thereby affecting 
DNA accessibility to transcriptional complexes [60, 120, 121].  Common 
modifications to histones include methylation, acetylation, phosphorylation, and 
ubiquitination [85]. Accumulating evidence suggests that transcriptional 
regulators facilitate these alterations, resulting in altered local gene transcription  
[85].  Thus, the structural interpretation of histone modifications may be 
responsible for the establishment and maintenance of discrete programs of gene 
expression that ultimately correspond with distinct biological outcomes.  Of equal 
importance, aberrations in global levels of histone methylation and acetylation 
are connected to the biology of cancerous lesions and their clinical outcome 
[122].  Although a number of histone lysine methyltransferases (HKMTs) are 
disrupted in a variety of cancer types [106, 123], how histone methylation 
mechanistically contributes to the oncogenic state is poorly understood. 
 The majority of HKMTs catalyze methyl transfer via the SET domain, a 
module encoded within many proteins that regulate diverse processes, including 
those critical for development and proper progression of the cell cycle [27, 60, 
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84, 124].  Histone lysine methylation on specific residues typically correlates with 
distinct states of gene expression [85].  Histone 3 (H3) contains most of the 
known targeted lysines of histone methyltransferases and thereby serves as a 
conduit of such epigenetic regulation.  In general, lysine methylation on H3K9, 
H3K27, or H4K20 corresponds with gene silencing, whereas methylation of 
H3K4, H3K36, or H3K79 is associated with actively transcribed genes [85].  
 Methylation of H3K36 which has been associated with actively transcribed 
genes [124, 125], appears to correspond primarily within coding regions.  H3K36 
methylation (H3K36me) by Set2 in yeast was recently observed to recruit an 
Rpd3-mediated histone deacetylase complex through direct recognition of 
H3K36me by the chromodomain of the Eaf3 subunit of Rpd3 [126-128].  Rpd3 is 
a histone deacetylase (HDAC) that has well-established functions as a 
transcriptional repressor [126]. It associates with several co-repressor 
complexes, including one that contains Pho23, Sds3, Sap30, Ume1, Cti6/Rxt1, 
and Sin3 [126]. However, recent evidence suggests that HDACs may also play a 
role during active transcription. As such, methylation of H3K36 is directly linked 
to histone deacetylation, via Rpd3-Sin3, that in turn functions to maintain 
chromatin structure during active transcription [126-128]. These findings reveal a 
new level of complexity with respect to histone modifications, and demonstrate 
our need to better understand the enzymes that catalyze these modifications. 
 Here, Smyd2 is identified as a member of a subfamily of SET domain 
containing proteins. As described in section 1.7, the Smyd family of proteins is 
defined by a SET domain that is split into two segments by an MYND domain, 
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followed by a cysteine-rich post SET domain [104].  While Smyd1 and Smyd3 
have been previously characterized [104, 106], nothing was known about the 
biochemical or functional properties of Smyd2, prior to these studies.  The 
findings reported here demonstrate that Smyd2 contains SET-domain dependent 
H3K36 HKMT activity. Smyd2 specifically associates with the Sin3A histone 
deacetylase complex, suggesting a link between two independent chromatin 
modification activities. Moreover, over-expression of Smyd2 in fibroblasts is 
shown to significantly suppress their growth.  It is therefore proposed that 
Smyd2-mediated chromatin modification regulates specific gene expression that 
has important implications for normal and neoplastic cell proliferation. 
 
3.3 Results 
3.31 Structural characteristics and expression of Smyd2 
 Although there are over 50 SET domain-containing proteins encoded in 
the human genome, only a fraction have been shown to methylate histones.  Of 
all the SET proteins, five cluster into a sub-family, Smyd, that contains a SET 
domain that is split into two segments by a MYND domain/zinc-finger motif, 
implicated previously in protein-protein interactions (Fig. 3.1A & C).  Members of 
this family are direct regulators of cancer (Smyd3) and essential developmental 
processes (Smyd1) [104, 106].  Thus, it is important to discern the biochemical 
and biological properties of Smyd2, given its high degree of homology to Smyd1 
and Smyd3. Data from Expressed Sequence Tags suggest that Smyd2 is 
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expressed in a wide range of normal, tumor, and diseased tissues.  To determine 
the tissues of highest gene expression, northern blotting was performed with a 
multiple tissue blot using probes specific to Smyd1, Smyd2, or Smyd3.  The 
northern analyses (Fig. 3.1B) demonstrate that in contrast to Smyd1, Smyd2 and 
Smyd3 transcripts are expressed more broadly in a wide variety of tissues.  
Smyd1 is expressed only in T lymphocytes, cardiac muscle, and skeletal muscle, 
as previously reported [129].  Smyd3 expression is highest in skeletal muscle 
[106] and thymus (Fig. 3.1B), although its transcripts are also highly detected in 
the brain, kidney, and ovary (Fig. 3.1B).  Tissues containing the highest levels of 
Smyd2 mRNA transcripts include heart, brain, liver, kidney, thymus, and ovary 
(Fig. 3.1B.)  Additionally, both Smyd2 and Smyd3 transcripts are detectable in 
embryonic mRNA, suggesting that as with Smyd1, Smyd2 and Smyd3 may be 
involved in development (Fig. 3.1B).  To determine which embryonic tissues 
manifest highest levels of Smyd2 transcripts, whole-mount in situ hybridization 
was performed using murine embryos at day 13.5 with a probe specific to 
Smyd2.  At this mid-gestation stage, Smyd2 transcripts are localized to the heart 
and the hypothalamus of the brain (Fig. 3.1E). 
 Immunohistochemical staining of Smyd1 and Smyd3 indicated that both 
proteins localize within the cytoplasm and nucleus of C2C12 [105] and Huh7 
cells [106], respectively.   To determine the subcellular localization of Smyd2, 
immunohistochemical staining was performed using a myc-tagged Smyd2 fusion 
protein.  Similar to Smyd1 and Smyd3, Smyd2 localizes within both the 
cytoplasm and the nucleus (Fig. 3.1D). 
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3.32 Smyd2 is a SET-dependent HKMT  
 Smyd2 contains the catalytic core residues of the SET domain shown to 
be critical for the histone methyltransferase activity of Smyd1 and Smyd3 (Fig. 
3.1C) [106, 130]. This suggests that Smyd2 may also possess HKMT activity.     
Histone methylation was tested after incubation of wild-type Smyd2-Myc (or 
Smyd3-Myc as a positive control) with S-adenosyl-L –[methyl-3H ] methionine 
(SAM) and mixed histones from calf thymus as a substrate.  A 17kD band 
corresponding to 3H-labelled H3 was seen with both Smyd3 and Smyd2 in the 
fluorogram (Fig. 3.2A, lanes 1 and 3), indicating that Smyd2 has intrinsic HKMT 
activity.  A tyrosine in the C-terminal region of the core SET domain is conserved 
among catalytically active SET domain proteins (Fig. 3.1C).  Therefore, to test if 
the SET domain is required for the HKMT activity observed for Smyd2, point 
mutations were made in this residue of Smyd3-Myc (Y239F) and Smyd2-Myc 
(Y240F).  Neither Smyd3 (Y239F)-Myc nor Smyd2 (Y240F)-Myc displayed HKMT 
activity (Fig. 3.2A, lanes 2 and 4).   
 Smyd2 HKMT activity was next tested on a recombinant histone H3 
substrate.  Wild-type Smyd2-Myc methylated H3 (Fig. 3.2C, lane 1) but Smyd2 
(Y240F)-Myc showed no HKMT activity (Fig. 3.2C, lane 2).  To test the activity of 
untagged Smyd2 protein, Smyd2 was expressed as a GST fusion in E. coli and 
the GST moiety was subsequently cleaved.  Methylation of recombinant histone 
octamers was tested after incubation with recombinant Smyd2.  Consistently, 
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recombinant Smyd2 was observed to methylate histone H3 (Fig. 3.2B, lane 1).   
Therefore, it is concluded that the Smyd2 has SET domain-dependent, intrinsic 
HKMT activity.   
 
3.33 Smyd2 dimethylates H3K36    
 Given that Smyd3 has been shown to have specificity for H3K4 [106], I 
tested whether Smyd2 has similar specificity. Histone methyltransferase assays 
were performed using recombinant H3, and specificity was determined by 
western blotting using antibodies against various methyl-lysine residues. The 
antibodies used in these assays include anti-dimethyl H3K4, anti-trimethyl H3K4, 
anti-dimethyl H3K9, anti-trimethyl H3K9, anti-trimethyl H3K27, anti-dimethyl 
H3K36, and anti-dimethyl H3K79.    A 17KD band corresponding to H3 was 
observed with Smyd3, but not with Smyd2, when reactions were probed with 
anti-dimethyl H3K4 (Fig. 3.2D, lanes 4 and 1, respectively) or anti-trimethyl 
H3K4. This indicated that Smyd2 has a different target specificity than Smyd1 or 
Smyd3.  Instead, the HKMT activity of Smyd2 was specific for H3K36, as 
determined by western blotting with anti-dimethyl H3K36 antibodies (Fig. 3.2E, 
lanes 1 and 4, respectively).  No additional residues appeared to be targeted by 
Smyd2 using the other antibodies listed above.   Therefore, it is concluded that 
Smyd2 dimethylates H3K36.  
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3.34 Smyd2 associates with HDAC1 and the Sin3 repression complex 
 Smyd3 induces transcriptional activation by binding to specific promoter 
sequences [106]. In contrast, when fused to GAL4, Smyd1 is known to repress 
transcription in an HDAC dependent manner [106]. Given that Smyd2 has activity 
towards H3K36, a mark associated with active transcription, the transcriptional 
regulatory activity of Smyd2 was tested. A GAL4-fusion protein was generated 
using Smyd2 and transient luciferase assays were performed in 10T1/2 cells.  
Unexpectedly, Smyd2-GAL4 inhibited transcription from an SV40 promoter that 
contained GAL4 binding sites (Fig. 3.3B), suggesting it may function similarly to 
Smyd1.  
 Although methylation of H3K36 is associated with actively transcribed 
genes, three recent reports have demonstrated that in yeast, methylation of 
H3K36 by Set2 recruits an Rpd3-Sin3 histone deacetylase complex [126, 128].  
The finding that Smyd2 possesses H3K36 methylation activity and functions to 
repress transcription in the above assay prompted us to investigate whether 
Smyd2 interacts with the human homologs of the Rpd3-Sin3 complexes.  In 
transient transfection experiments in 293T cells, the human homolog of Rpd3, 
HDAC1, interacted specifically with Smyd2-GAL4 upon immunoprecipitation with 
anti-GAL4 antibodies (Fig. 3.3C).  Consistently, when cell extracts from 293T 
cells over-expressing Smyd2-GAL4 were immunoprecipitated with anti-GAL4 
antibody, the immune complexes contained endogenous Sin3A (Fig. 3.3D).  In 
contrast, Smyd2-GAL4 failed to coimmunoprecipitate FLAG-tagged MBD3 and 
MTA2, components of the HDAC1-containing NuRD complex (Fig. 3.3D).  Thus, 
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it is concluded that Smyd2 preferentially interacts with distinct HDAC1-containing 
complexes, namely Sin3A. 
 
3.35 Smyd2 suppresses cell proliferation 
 The role of Smyd3 in transcriptional regulation as a histone 
methyltransferase has been linked to its ability to augment cellular proliferation 
[106].  To investigate the effects that Smyd2 may have on cell proliferation, 
NIH3T3 cells were transfected with either Smyd2-Myc or Smyd3-Myc.  Relative 
to a mock control and consistent with previous findings [106], over-expression of 
Smyd3 markedly increased cell growth (Fig. 3.4).  Conversely, the transfection of 
3T3 cells with Smyd2 led to a decrease in their proliferation (Fig. 3.4), indicating 
a potential role for Smyd2 in the maintenance of cell-cycle progression.  
 
3.36 Status of Smyd2 conditional knockout 
 Targeted deletion of Smyd2 will be accomplished by crossing tissue-
specific or ubiquitously expressing Cre into Smyd2 homozygous floxed mice.  
The targeting vector (Fig. 3.5A) contains a short (0.6kb) and a long (7.4 kb) arm 
of homology, a neomycin resistance cassette (neo) for positive selection, and a 
thymidine kinase cassette for negative selection.  Two site-specific recombination 
sites are employed in vivo.  (1) Flp recombinase is used to delete the neo marker 
from the mouse germline, and (2) Cre recombinase is used to conditionally 
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delete Smyd2 in selected tissues.  Two loxP sites flank the region to be deleted.  
This region includes exon 1 of Smyd2.   
 Details relevant to the creation of the Smyd2 conditional targeting 
construct are provided in the Materials & Methods (chapter 2.13).  Briefly, to 
create the Smyd2 conditional targeting construct, two genomic fragments were 
first subcloned from a C57BL/6 murine Bac clone.  These included a 2.2kb 
fragment containing exon 1 and a fragment containing 5.2kb of intronic sequence 
between exons 1 and 2.  A third fragment, containing 0.6kb upstream of exon 1, 
was generated using C57BL/6 genomic DNA as template (primers provided in 
chapter 2.13).  Each fragment was consecutively inserted into unique sites of a 
destination targeting construct (pDELBOY [118]) and the completed targeting 
construct was linearized at the short arm of homology.  C57BL/6 ES cells were 
then transfected and selected with G418 and gancyclovir.   
 Successfully targeted ES cells were identified by Southern analyses.  
These assays were performed across the long arm of homology (Fig. 3.5B) and 
the short arm of homology (Fig. 3.5C) of clones that had experienced 
homologous recombination at the Smyd2 locus.  A size difference allowed the 
separation of targeted allele and wild type allele.  These clones were then 
injected into C57Bl/6J-tyr©-2J (an albino strain) blastocysts, which were 
implanted into the uteri of psuedopregant recipients and ultimately chimeras were 
born.  The chimeras were mated to albino C57Bl/6 females and resulting progeny 
with a black coat color were genotyped.  Mice that were shown to be 
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heterozygous for the targeted allele were mated to Flip recombinase-expressing 
transgenic mice to remove the neo cassette. 
 Presently, we have 5 mice in which the neo cassette has been removed 
(floxed).  They are currently being crossed with wild-type C57Bl/6 mice to remove 
the flp transgene.  In a tandem effort to analyze a Smyd2 hypomorph, in which 
the presence of a neo cassette disrupts the promoter region of Smyd2, we have 
bred one mouse to homozygosity for the presence of neo.  This male mouse 
exhibits no marked phenotype, to date.  It will be crossed with females which are 
heterozygous at this allele in a series of timed matings to obtain mouse 
embryonic fibroblasts (MEFs) which are homozygous for the presence of neo.  
Although the our ultimate goal is to produce floxed/floxed homozygous mice from 
which Smyd2 can be conditionally removed, we hope that obtaining hypomorphic 
MEFs in the meantime will provide us with an intermediate cell line that will 




 Great strides have been made in the interpretation of covalent histone 
modifications regarding their role in transcriptional regulation.  Histone lysine 
methylation has been found to affect the structure of chromatin thereby 
establishing complex patterns of gene expression [131].  In some cases, these 
patterns are clearly defined.  For example, H3K4 methylation is most often 
 45
associated with the establishment of euchromatin and the consequent activation 
of local gene expression [121].  Reciprocally, methylation at H3K9 is commonly 
involved with the formation of heterochromatin and the ensuing silencing of 
nearby gene transcription [120, 121].   
 Initial data on the yeast HKMT, Set2, indicated that it functions in 
transcriptional repression by methylating H3K36 [132].  However, the HKMT 
activity of Set2 was later linked to the elongation phase of RNA polymerase II 
(RNAPII) [109, 133].  Likewise, in a more contemporary study, an analysis of the 
distribution of H3K36 methylation in metazoans correlated this modification with 
actively transcribed genes [124].  Most recently, methylation of H3K36 by Set2 
has been associated with the recruitment of a histone deacetylase complex, 
Rpd3 [126].  The overall role and implications of histone deacetylation within the 
coding regions of active genes is still unclear.      
 In mammalian epigenetics, NSD1 was one of the first HKMTs reported to 
act on H3K36 [134].  Whether NSD1 functions in the activation or repression of 
transcription has yet to be determined.  A recent investigation reported that the 
human HYPB protein methylates H3K36 and that this enzymatic activity is 
required for the role of HYPB as a transcriptional activator [135].   
 The present findings introduce Smyd2 as a H3K36-specific HKMT that 
acts as a transcriptional repressor.  Clearly, there are other transcriptional 
regulatory mechanisms at work in conjunction with the methylation of H3K36.  It 
seems that the more we learn about where histone marks are localized and what 
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proteins facilitate the process, the less we are certain about how such 
localization ultimately contributes to gene regulation.  Although this complicates 
our ability to apply a broad interpretation of histone modifications, it provides a 
clear direction for the pursuit of a deeper fold in the histone code.     
 
3.41 Smyd2 regulatory functions     
 Transcriptional assays demonstrated that Smyd2 can repress transcription 
from a luciferase reporter gene (Fig. 3B).  A recent study in yeast demonstrated 
that methylation of H3K36 recruits a histone deacetylase complex, Rpd3 [126].  
Concurrently, another group concluded that H3K36 methylation-induced 
recruitment of an Rpd3 complex resulted in the reversal of lysine acetylation 
related to the elongation phase of RNAPII, suggesting that it functioned to stem 
intragenic transcription initiation [128].  This is reminiscent of the mechanism by 
which the FACT complex functions.  That is, as the elongation complex traverses 
a coding region, FACT facilitates both destabilization of the chromatin structure, 
to impart efficient and processive elongation, as well as reorganization of the 
chromatin to prevent intragenic initiation of transcription [136].  Whereas H3K36 
methylation recruits the Rpd3 complex, it has been suggested that FACT 
recruitment may occur through its association with CHD1, which recognizes 
trimethylated H3K4 [137].  As the Rpd3 complex is known to contain Sin3 [126], it 
was particularly informative to find that Smyd2 also associates with Sin3.  It will 
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be of further interest to determine whether in vivo recruitment of Sin3 requires 
H3K36 methylation, the presence of Smyd2, or both.     
 Over-expression of Smyd2 in NIH3T3 cells significantly reduces cell 
proliferation.  In a previous study, cell proliferation assays demonstrated that 
Smyd3 augmented cell growth when introduced into NIH3T3 cells [106].  It is well 
established that cell proliferation and differentiation are coordinated by 
synchronized patterns of gene transcription.  In the case of Smyd3, enhancement 
of cell growth has been shown to be dependent upon the HKMT activity of the 
Smyd3 protein [106].  It will be informative to determine whether the suppressive 
effect of Smyd2 on cell growth requires its function as an H3K36-specific HKMT.  
Such a determination, in tandem with identification of the putative gene target 
specificity of Smyd2, will provide a broader mechanistic model of how the Smyd 
family may function.  
 Histone lysine methylation is more stable than other known post-
translational modifications, persisting as long as several rounds of cell division 
[131, 138, 139].  This makes lysine methylation potentially valuable in diverse, 
long-lasting signaling networks, not only in the nucleus for histone and non-
histone proteins, such as p53 and TAF10, but conceivably in the cytoplasm as 
well.  The findings that Smyd1 and Smyd3 can localize in the cytoplasm [105, 
106] along with my observation that Smyd2 is also capable of cytosolic 
localization, lends credence to this idea.  This argument is further strengthened 
by the finding that Smyd1 moves from the nucleus to the cytoplasm during 
myogenic differentiation [105].  Another SET domain-containing HKMT, Ezh2 and 
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its partners Eed and Suz12, reside primarily in the cytoplasm of various mouse 
and human cells [140, 141].  Within the nucleus, the Ezh2 complex catalyzes 
H3K27 methylation, whereas the cytosolic Ezh2 binds Vav1, a controller of Rho 
family GTPases, and Ezh2 is important for signaling events previously attributed 
to Vav1 [140-142].  There is no evidence that Ezh2 methylates Vav1, so the 
significance of lysine methylation in the cytoplasm remains unclear.  Therefore, 
an important next-step in the characterization of Smyd2 will be to test the role of 
Smyd2-mediated lysine methylation in the formation of stable and potentially 
heritable cytosolic signaling complexes with Smyd2 interaction partners and to 
track these complexes, once formed, within resting and dividing cells.   
 
3.42 Implications for the Smyd Family  
 The Smyd HKMTs are set apart from other such chromatin modifying 
enzymes by the split nature of their SET domains.  The SET domain of each 
Smyd protein is divided by a MYND domain (Figure 3.1A & C), a zinc-finger motif 
that mediates protein-protein interactions.  This domain is found in several 
transcriptional regulators shown to mediate distinct biological functions [107, 
108].  For example, the MYND domain of Smyd1 is essential for its interaction 
with the muscle-specific transcription factor, skNAC [105].  Additionally, ETO, a 
common target of chromosomal translocations in acute myeloid leukemia, directs 
transcriptional repression through an intact MYND domain [107].  Thus, the 
importance of the MYND domain in gene regulation has been well established 
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and it may provide some insight into other mechanisms at work through Smyd2 
that affect the overall outcome of its activity in transcriptional regulation.  The 
complete function of Smyd2 in vivo is likely dependent upon other proteins and 
complexes, in addition to HDAC1 and Sin3A, with which it associates.   
 Northern blot analyses revealed that Smyd2 and Smyd3 are expressed in 
a wide variety of tissues (Fig. 1B) whereas Smyd1 is more restricted in its tissue 
distribution [129].  Studies of ours and others on Smyds1, 2, and 3 suggest that 
Smyd family members function through a common mechanism, specifically, 
lysine methylation.  It is reasonable to assume that individual Smyd proteins 
associate with different transcription factors and other effector proteins that 
ultimately dictate specific gene regulation.  The significant expression of Smyd2 
in the in embryonic heart (Fig. 3.1B, E) suggests that as with Smyd1, Smyd2 may 
regulate cardiac development. The identification of the biological functions of 
Smyd family proteins will undoubtedly reveal new insights into the relationships 









 I conclude that Smyd2 dimethylates H3K36 and that HDAC1-mediated 
deacetylation of the coding regions of active genes is potentially linked to the 
histone methyltransferase activity of Smyd2.  I further propose that this role of 
Smyd2 in the regulation of gene expression ultimately restrains cell proliferation.  
As it is clear from this study, future research on Smyd proteins, with strong 
emphasis on the unique organismal context, will shed light onto the biological 
functions of Smyd family proteins, revealing new and fascinating insights into the 
relationships between chromatin modifications and the development and 















Figure 3.1 Alignment of the mammalian Smyd family proteins and Smyd2 
localization. (A) Schematic representation of the five mammalian Smyd proteins. 
The split SET domain is shown in light gray; the MYND domain is represented in 
black and the cysteine-rich post-SET domain is displayed in dark gray. Positions of 
the amino acids are indicated. (B) Expression of Smyd1, Smyd2, and Smyd3 
transcripts in tissues. Top panel: Smyd3 mRNA is most highly expressed in the 
thymus. Middle panel: Smyd2 mRNA is most highly expressed in the heart and 
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brain. Bottom panel: Smyd1 expression is restricted to the heart and skeletal muscle 
[104]. Transcripts for Smyd1, Smyd2, and Smyd3 are expressed in the embryo. (C) 
ClustalW alignment of the amino-terminal SET residues, the MYND domain, and the 
core SET residues followed by the post-SET domain present in Smyd1, Smyd2, 
Smyd3, Smyd4, and Smyd5. (D) Smyd2 is localized to the cytoplasm and the 
nucleus. Exponentially growing 293T cells were transfected with 1 μg of plasmids, 
encoding myc tagged Smyd2. 48 hr post-transfection, cells were fixed, washed, 
permeabilized and exposed to monoclonal mouse anti-myc antibody. Nuclei were 
counterstained with DAPI. Right panel: Smyd2 (red) localizes to both the nucleus 
and the cytoplasm of 293T cells. Left panel: Nuclei were counterstained with DAPI 
(blue). The experiments were repeated in triplicate with identical results. (E) Smyd2 
mRNA is localized in the heart and hypothalamus of the brain at E13.5. Whole-
mount in situ hybridization of Smyd2 transcripts in embryos at day 13.5 post coitus 
were prepared by exposition of sense (right panel) and antisense (middle panel) 
DNA probes, specific to Smyd2 to the sections. Whereas hybridization with sense 
probe resulted in no signal (right panel), thus, serving as control, Smyd2 mRNA is 
easily detected in the heart and the hypothalamus of the brain in embryos at day 












Figure 3.2:  Smyd2 dimethylates histone H3, lysine 36. (A) Smyd2 methylates 
histone H3 in an in vitro histone methyl transferase (HKMT) assay using mixed 
histones from calf thymus as substrate. Fluorograms are shown in the upper 
panel; the 17 kD band, corresponding with Histone H3, is indicated; Coomassie 
stained SDS-PAGE gels were used to verify equal loading and are depicted in 
the lower panels. Lanes 1 and 3 show positive HKMT activity at H3 by myc 
tagged Smyd3 and myc tagged Smyd2, respectively. Lanes 2 and 4 indicate that 
neither the Smyd3 (Y239F) nor the Smyd2 (Y240F) catalytic mutants have HKMT 
activity. It is concluded that the HKMT activity of Smyd3 depends on Y239 and 
 54
Y240 for Smyd2. (B) Smyd2 methylates Histone H3 in an in vitro histone methyl 
transferase assay using recombinant octamers as substrate. Fluorograms are 
shown in the upper panel; the 17 kD band, corresponding with Histone H3, is 
indicated; Coomassie stained SDS-PAGE gels were used to verify equal loading 
and are depicted in the lower panels. Histone H3 was found methylated by 
Smyd2 using recombinant octamers as substrate in an in-vitro HKMT assay. (C) 
Smyd2 methylates histone H3 in an in vitro histone methyl transferase assay 
using recombinant histone H3 as a substrate. Fluorograms are shown in the 
upper panel; the 17 kD band, corresponding with histone H3, is indicated; 
Coomassie stained SDS-PAGE gels were used to verify equal loading and are 
depicted in the lower panels. Histone H3 was found methylated by Smyd2 using 
recombinant octamers as substrate in an in-vitro HKMT assay (lane 1). The 
catalytically defective mutant Smyd2 (Y240F) failed to methylate recombinant 
histone H3 (lane 2). It is concluded that the HKMT activity of Smyd2 depends on 
Y240. (D) Smyd2 does not dimethylate histone H3 at lysine 4 using recombinant 
histone H3 as a substrate in an in-vitro HKMT assay. Western results, using 
antibodies, specifically reactive with dimethylated histone H3, lysine 4, are 
shown; the 17 kD band, corresponding with histone H3, is indicated. Lanes 1 and 
4 indicate that immunoprecipitated and myc-tagged Smyd3, but not myc-tagged 
Smyd2, dimethylates histone H3 at lysine 4. Lanes 2 and 5 show that neither 
Smyd2 (Y240F) nor Smyd3 (Y239F) dimethylate histone H3 at lysine 4. We 
conclude that Smyd2 does not dimethylate histone H3 at lysine 4. (E) Smyd2 
dimethylates histone H3 lysine 36 using recombinant histone H3 as a substrate 
in an in-vitro HKMT assay. Western results, using antibodies, specifically reactive 
with dimethylated histone H3, lysine 36, are shown; the 17 kD band, 
corresponding with histone H3, is indicated. Lanes 1 and 3 indicate that Smyd2 
dimethylates recombinant histone H3 at lysine 36, independent of the myc or 
Gal4 tag. The catalytically inactive mutant Y240F does not dimethylate 
recombinant histone H3 at lysine 36 (lane 2). Smyd3, as well as the catalytically 
defective mutant Y239F, do not dimethylate recombinant histone H3 at lysine 36 
(lanes 4 and 5). We conclude that Smyd2 dimethylates recombinant histone H3 
at lysine 36, whereas Smyd3 does not display this activity. (Adapted from Brown, 





Figure 3.3: Smyd2 associates with the Sin3 repression complex and is 
involved in transcriptional repression. (A) Expression of GAL4-Smyd2 fusion 
protein in 293T cells.  293T cells were transfected with the constructs indicated and, 
48 hours post transfection, whole cell lysate was prepared using RIPA buffer and 
subjected to western analysis using antibodies directed against the GAL4 tag. A 
reactive band was detected at the appropriate molecular weight (approximately 66 
kD). Extracts from cells, transfected with the GAL4-DBD construct [17], served as 
negative control. (B) Smyd2 represses transcription of a luciferase reporter. Top 
panel: Schematic illustration of the reporter construct used. Bottom panel: 10T1/2 
cells were transiently co-transfected with the 5XGAL4-SV40-luciferase reporter (1 
μg) together with GAL4-DBD or GAL4-Smyd2 (2 μg each).  Percent activity of the 
luciferase was determined in relation to GAL4-DBD. Smyd2 significantly represses 
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the transcription of a luciferase reporter in 10T1/2 cells. (C) Smyd2 associates with 
HDAC1. Exponentially grown 293T cells were transiently co-transfected with GAL4-
DBD or GAL4-Smyd2, together with Flag-tagged HDAC1 (HDAC1-F). Whole cell 
RIPA extracts were immunoprecipitated using an anti-GAL4 antibody and 
immunoblots were probed with an anti-FLAG antibody. As shown here, Smyd2 
associates with HDAC1. RIPA whole cell extracts from GAL4-DBD transfected cells 
[17] served as negative control. Equal protein amounts in the immunopreciptation 
assays were demonstrated by analysis of 5% input using anti Flag antibodies. (D) 
Smyd2 interacts with the Sin3A but not the NuRD complex. Exponentially grown 
293T cells were transfected with the constructs indicated and, 48 hours post 
transfection, whole RIPA lysate was prepared. Antibodies directed against GAL4 
were used for immunoprecipitation, followed by western analysis using the 
antibodies indicated. Smyd2 associates with HDAC1 and Sin3A but not with the 


















Figure 3.4:  Smyd2 suppresses NIH3T3 cell proliferation. NIH3T3 cells were 
transfected with plasmids encoding myc-tagged Smyd2 or myc-tagged Smyd3. Cells 
transfected with the empty expression construct (Mock) served as control. All cells 
were monitored by cell counting using trypan blue exclusion. The inserts show the 
level of expression of Smyd2-myc and Smyd3-myc at 24 and 144 hours post 
transfection, demonstrating similar levels of ectopically introduced proteins in the 
NIH3T3 cell lines used. Whereas ectopically introduced Smyd3 enhanced the 
proliferation, Smyd2 displayed a negative effect on the growth rate of NIH3T3 cells. 






Figure 3.5: Strategy for the conditional targeting of the Smyd2 gene.  (A) 
Schematic illustration of the targeting construct.  The targeting vector has a short 
(0.6kb) and a long (7.4 kb) arm of homology, a neomycin cassette (pgk-neo) for 
positive selection, and a thymidine kinase cassette (pgk-hsv-tk) for negative 
selection.  Two site-specific recombination sites are employed in vivo.  (1) Flp 
recombinase to delete the neo marker from the mouse germline, and (2) Cre 
recombinase to conditionally delete Smyd2 in selected tissues.  Two loxP sites 
flank the region to be deleted.  Enzyme restriction sites are indicated.  (B and C)  
Characterization of successfully targeted embryonic stem (ES) cells by Southern 
analysis.  Southern analyses were performed across the long (panel B) and the 
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short (panel C) arms of homology of clones that have experienced homologous 
recombination at the Smyd2 locus.  A size difference allows the separation of 
targeted allele (ta) and wild type (wt) allele.  Fragment size is indicated in kilo 
base pairs (kb).  The restriction enzymes used for analyses are indicated at the 






















4.  PROMISCUITY OF SMYD3-MEDIATED METHYLATION 
 
4.1 Abstract 
 Aberrant expression of the histone H3-lysine 4 (H3K4)-specific 
methyltransferase, Smyd3, has been implicated in colorectal, hepatocellular, and 
breast cell carcinogenesis.  Here, Smyd3 is also shown to target histone H4, 
lysine 20 (H4K20).  However, over-expression of Smyd3 in fibroblasts results in 
global reduction of trimethylation at H4K20 and this is accompanied by a striking 
increase in cell proliferation.  As the methylation of H3K4 and H4K20 are 
normally associated with conflicting biological roles, I predict that these 
differential activities of Smyd3 are manifest under spatially and/or temporally 
distinct conditions, in the presence of different associating complexes, thereby 
resulting in effects that may be antagonistic of one another.     
 
4.2 Background 
 In the developed world, colorectal carcinoma (CRC) is the primary source 
of malignancy associated with cancer deaths [106, 143, 144].  Worldwide, 
hepatocellular carcinoma (HCC) accounts for the predominant cause in cancer 
mortalities and the occurrence of this type of tumor is increasing at an alarming 
rate in the United States [145].  As changes in chromatin accessibility appear to 
play a central role in the progression of such neoplasias, significant effort is being 
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invested toward understanding the molecular mechanisms that govern the 
dynamic architecture of chromatin [146, 147].  
 Cellular characteristics are retained through epigenetic mechanisms that 
impart heritable blueprints for gene expression [107, 148].  These histone codes 
are commonly expressed through post-translational modifications at specific 
histone residues in a chronologically-sensitive manner [60, 149].  Common 
modifications include methylation, acetylation, phosphorylation, and 
ubiquitination [149].  The transcriptional interpretation of these programmed 
events corresponds with distinct biological outcomes [107].   
 Smyd3 has been identified as a H3K4-specific methyltransferase [106].  
This modification often acts in concert with alterations in DNA methylation to 
impart permanent specificity of cell-type facilitated through long-term gene 
expression [108].  The findings that Smyd3 is substantially upregulated in most 
CRCs [150], HCCs [151], and breast cancer tissues [152] support a paradigm in 
which aberrant expression of chromatin-modifying enzymes, leading to a 
disturbance in established epigenetic patterns, can ultimately result in 
tumorigenesis.  
 Through microarray analyses, 80 genes have been identified that display 
altered gene expression in the presence of Smyd3 [106].  Notably, one of these 
is Nkx2.8, a homeobox gene that exhibits upregulation in hepatocellular 
malignancies [153].  Other affected genes include cell cycle regulators, 
oncogenes, and several that are critical in developmental processes [106].  In 
 62
concert with the idea that Smyd3 is a transcriptional activator, it forms a complex 
with RNA polymerase II and it was also shown to bind DNA directly by way of a 
sequence found in the promoter of Nkx2.8 [106].  These findings not only provide 
targets for the H3K4 enzymatic activity of Smyd3 but they also implicate two 
methods for its direct interaction with those genes (Fig. 4.1 A & B).   
 Figure 4.2 illustrates a likely paradigm in which the aberrant expression of 
Smyd3 may result in the upregulation of otherwise silent genes such as Nkx2.8.  
This can disrupt the balance of cellular gene expression, ultimately resulting in 
transformation.  This idea is corroborated not only indirectly, by the findings that 
Smyd3 is over-expressed in CRCs, HCCs, and breast cancers, but also more 
directly by the effect that Smyd3 has on cell proliferation.  The over-expression of 
Smyd3 in NIH3T3 cells accelerates propagation while siRNA knockdown of 
Smyd3 reverses these effects [106]. 
  
4.3 Results 
4.31 Smyd3 enzymatic activity 
 As mentioned above, Smyd3 had previously been identified as a histone 
H3K4-specific methyltransferase.  However, in their ground-breaking publication, 
Hamamoto et al. failed to examine any potential substrates for Smyd3, beyond 
recombinant histone H3 [106].  Therefore, to examine the possibility that Smyd3 
may have more than one histone substrate, I examined its ability to methylate 
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mixed histones isolated by acid extraction from HeLa cells.  Histone methylation 
was tested after incubation of Smyd3 with S-adenosyl-L-[methyl-3H ] methionine 
(SAM) and the mixed histones from HeLa cells as a substrate.  A 17kD band 
corresponding to 3H-labelled H3 was visible in the lane containing Smyd3 on the 
fluorogram (Fig. 4.3A), confirming that Smyd3 has intrinsic H3-specific activity.  
Surprisingly however, a more intense band corresponding with a smaller 
molecular weight was also observed, indicating that in addition to methylating H3, 
Smyd3 also methylates one or more of the diminutive histones (H2A, H2B, 
and/or H4).     
 Smyd3 HKMT activity was next tested separately on recombinant histone 
H2A, H2B, H3, and H4 substrates.  Smyd3 methylated all of the histones to 
various degrees (Fig. 4.3B).  As H4 appeared to be the most vigorously 
methylated substrate, I concentrated my efforts on confirming the activities of 
Smyd3 on H4.  A tyrosine in the C-terminal region of the core SET domain is 
conserved among catalytically active SET domain proteins (Fig. 4.3B).  
Therefore, to confirm the authenticity of Smyd3 as a SET-dependent HMTase 
capable of methylating both H3 and H4, a catalytic mutant of Smyd3 (Smyd3-
Y239F-Myc, see chapter 3.4) was analyzed for its ability to methylate H3 and H4 
as compared with wild-type (Smyd3-myc).  Smyd3-Y239F-Myc displayed 
absolutely no HKMT activity on either H3 or H4 (Fig. 4.3C).  However, the wild-
type Smyd3-Myc displayed activity in the presence of both H3 and H4 (Fig. 
4.3C).  Therefore, I concluded that Smyd3 has SET domain-dependent, intrinsic 
HKMT activity for both H3 and H4 substrates. 
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 Given that the only documented mammalian site of lysine methylation on 
histone H4 is at H4K20 [154], I tested whether H4K20 is the residue targeted by 
Smyd3.   Histone methyltransferase assays were performed using recombinant 
H4, and specificity was determined by western blotting using antibodies against 
monomethyl H4K20 and trimethyl H4K20.  Smyd1B was included as a negative 
control.  No band corresponding with H4 was detected when reactions were 
probed with anti-monomethyl H4K20 (Fig. 4.4B).  However, when reactions were 
probed with anti-trimethyl H4K20, a band corresponding to H4 was observed with 
Smyd3, but not with Smyd1 (Fig. 4.4C.).  Therefore, it is concluded that Smyd3 
trimethylates H4K20.         
 To strengthen these findings, I performed a series of proximity bead 
histone methyltransferase assays using Smyd3 with four different H4 peptides 
varying only with regard to their methylation state at K20.  Trimethylated H4K20 
was included as a negative control.  According to scintillation counts, Smyd3 
activity was strongest on a dimethylated H4 peptide (Fig. 4.4A).  This is in accord 
with the H4K20 antibody results.  Modest activity was also observed on a 
monomethylated H4 peptide (Fig. 4.4A).  However, scintillation counts 
demonstrated that non-methylated H4 peptides are not strongly acted upon by 





4.32 Effects of Smyd3 on global methylation patterns 
 Cell differentiation is driven by the progressive regulation of gene 
expression patterns that favor distinct cell types [155].  Histone modifications 
govern many of these regulatory processes by their effects on chromatin 
accessibility and the recruitment of either transcriptional-activation or -repression 
complexes [156].  For example, global levels of histone acetylation and H3K4 
methylation, which are most often associated with transcriptionally active 
chromatin, decline during the differentiation of embryonic stem (ES) cells [157].  
Reciprocally, the levels of H4K20 and H3K9 trimethylation, which are most often 
connected with gene silencing, are elevated during the differentiation of ES cells 
[158].  These findings indicate that global transcriptional competence becomes 
more constrained during cell differentiation.  Conversely, the re-initiation of 
pluripotency in somatic cells requires the re-establishment of histone 
modifications that are conducive to the formation of transcriptionally active 
euchromatin, including elevated levels of global acetylation and H3K4 
methylation [159].  
 Recent advances in cancer research make it increasingly evident that 
oncogenesis often arises from aberrations in patterns of gene expression that 
define and maintain cellular memory [160].  In fact, almost all classes of cancer 
involve deviant epigenetic modifications that impart heritable changes necessary 
for tumorigenesis and metastatic progression [161-164].  Studies showing that 
the H3K4-specific methyltransferase acitivity of Smyd3 is involved in several 
types of cancer [106, 152] are in accord with other research that correlates 
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increases in global methylation at H3K4 with augmented cell proliferation [160-
162].  However, my recent findings, demonstrating that Smyd3 is also competent 
in the trimethylation of H4K20, complicate this matter.  Although Smyd3 has been 
shown to methylate H3K4 near the promoters of specific genes which it is known 
to upregulate, the effect of Smyd3 on global methylation at H3K4 has not been 
evaluated.  To clarify the paradoxical specificities of Smyd3 at H3K4 and H4K20, 
I analyzed the global methylation patterns associated with the expression of 
Smyd3 in fibroblasts.     
 To determine if the over-expression of Smyd3 affects global methylation 
patterns in fibroblasts, I conducted a series of transfection experiments in which I 
over-expressed wild type Smyd3-Myc or Smyd3 (Y239F)-Myc in NIH3T3 cells.  
After 36 hours, I isolated histones from the transfected cells by acid extraction 
and conducted a series of western blots on the resulting fractions using the 
following antibodies:  anti-trimethyl H3K4; anti-trimethyl H3K9, and anti-trimethyl 
H4K20.  Levels of H3K4 and H3K9 trimethylation appeared unchanged in the 
presence of either wild type Smyd3 or its catalytic mutant, relative to that 
observed on histones from mock transfected cells (Fig. 4.5B).  However, histones 
from cells transfected with wild type Smyd3 exhibited a marked decrease in 
H4K20 trimethylation when compared to histones from mock transfected cells 
(Fig. 4.5A).  Therefore, I concluded that over-expression of Smyd3 results in a 
significant decrease in the global methylation of H4K20 in NIH3T3 cells.  
Furthermore, over-expression of Smyd3 does not affect global methylation at 
H3K4 or H3K9 in NIH3T3 cells.     
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4.33 Production of a Smyd3 polyclonal antibody 
 As the methylation of H3K4 and H4K20 are normally associated with 
conflicting biological roles, it seems reasonable to speculate that the differential 
activities of Smyd3 are manifest under spatially and/or temporally distinct 
conditions, in the presence of different associating complexes, thereby resulting 
in effects that may be antagonistic of one another.  Therefore, to facilitate our 
investigation of endogenous Smyd3 expression and its interacting 
partners/complexes, I produced a polyclonal antibody that specifically reacts with 
Smyd3.   
 Recombinant human Smyd3 was commercially produced using a 
baculoviral infection system in which an ovarian cell line from Spodoptera 
frugiperda served as the host.  I generated Smyd3 polyclonal antibodies by 
immunizing New Zealand White rabbits four times each with purified Smyd3.  
Rabbit serum was collected before immunization as a negative control.  The 
specificity of the Smyd3 antibody was tested by comparing its reactivity on 
western blots arrayed with lysates from 293T cells over-expressing Smyd3 fusion 
proteins versus lysates of 293T cells over-expressing Smyd1 and Smyd2 fusion 
proteins (Fig. 4.6A & B).  At a dilution of 1:2000, the Smyd3 polyclonal antiserum 
was highly reactive against Smyd3 fusion proteins but completely inert toward 
Smyd1 and Smyd2 fusion proteins.  Smyd3 polyclonal antibody was then used to 
analyze the expression of Smyd3 proteins in adult murine tissues.  At a 1:2000 
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dilution, Smyd3 protein was detected in adult heart and liver tissues but not in 
spleen (Fig. 4.6C).  Finally, the Smyd3 antibody was used to determine if Smyd3 
is highly expressed in common cell lines.  Smyd3 was detectable in two T-cell 
lines (Jurkat and Molt-13; data not shown).  These tissue and cell lysate western 
blots correspond with previous northern blots indicating that Smyd3 transcripts 
are expressed in thymus, liver, and cardiac tissues but not in spleen.   
 
4.4 Discussion 
 Lysine-rich N-terminal tails project from within the histone core of 
chromatin and are the targets of a variety of post-translational modifications 
[165].  These alterations impact the degree of chromatin condensation which, in 
turn, regulates transcriptional activity [166].  Histone methylation is one such 
modification and it has been shown to be critical in the establishment of heritable 
patterns of gene expression [167].  Numerous studies have associated aberrant 
histone methylation with the induction and progression of human disease [168].  
For this reason, there is growing interest in the identification of the enzymes 
responsible for histone methylation and the ramifications of their potential for 
deviant activity [169].  Smyd3 has, therefore, emerged as the subject of intense 
research for its role as a histone methyltransferase involved in the induction of 
hepatocellular, colorectal, and breast cancers [106, 152]. 
 The correlation between Smyd3 over-expression in mature tissues and 
tumorigenesis prompted our functional analysis of Smyd3.  To this end, we have 
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determined that Smyd3 is promiscuously competent in the methylation of histone 
residues.  In addition to its previously identified target at H3K4, Smyd3 robustly 
trimethylates H4K20 in vitro.   The biological effects of Smyd3 appear to be 
tissue-specific as over-expression of Smyd3 in fibroblasts results in a global 
reduction of trimethylation at H4K20.  Therefore, we have produced a highly 
specific polyclonal antibody against Smyd3 to facilitate our investigation of 
endogenous Smyd3 expression and its interacting partners/complexes.   
 
4.41 Smyd3 enzymatic activity 
 Using recombinant human Smyd3, I confirmed the authenticity of Smyd3 
as a SET-dependent histone methyltransferase, capable of methylating histone 
H3.  In addition, I found that Smyd3 is also competent as a catalyst of histone H4 
methylation.  Although dual-specificity methyltransferases have been previously 
identified [170], they are certainly rare.  SET9 for example, is known to methylate 
H3K4 [171] as well as lysine 372 of p53 [172].  Likewise, the ability of enzymes to 
methylate more than one histone residue is exceptionally rare [173].  One such 
enzyme, Drosophila Ash1, is recognized for its capacity to methylate H3K4, 
H3K9, and H4K20.  However, its mammalian ortholog is specific only for H3K36 
[174].  In the case of Drosophila Ash1, the multiple methylation sites have been 
demonstrated to work synergistically to induce transcriptional activation by 
recruiting chromatin remodeling factors and preventing the binding of 
transcriptional repressors [173].  Likewise, H3K4 methylation by Smyd3 has been 
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linked to transcriptional activation and Smyd3 is known to interact with RNA 
polymerase II and HELZ, both of which are associated with actively transcribed 
euchromatin [106].  However, we have also shown that Smyd3 interacts with the 
nuclear receptor co-repressor, N-CoR, and the Sin3 transcriptional repression 
complex (Fig. 4.7).  Therefore, although it is reasonable to speculate that the 
dual-specificities of Smyd3 function synergistically in a manner analogous to 
Drosophila Ash1, it is just as likely that each specificity functions separately.  In 
the latter paradigm, one can imagine that the differential activities of Smyd3 are 
manifest under spatially and/or temporally distinct conditions, in the presence of 
different associating complexes, thereby resulting in effects that may be 
antagonistic of one another.  Indeed, the contradictory physiological 
consequences of H3K4 trimethylation versus H4K20 trimethylation parallel the 
distinct biological roles associated with RNAPII transcriptionally active complexes 
versus the N-CoR and Sin3 transcriptional repression complexes.  In the context 
of pharmacologically impairing the activity of Smyd3 in a therapeutic intervention 
against cancer, the answers to these uncertainties are paramount.  Specifically, it 
must be known whether the global inhibition of Smyd3 in vivo will result in 






4.42 Potential role for Smyd3-mediated reduction of global trimethylation at 
H4K20 
 Using antibodies against several common sites of histone methylation, I 
determined that over-expression of Smyd3 reduces global trimethylation at 
H4K20 in fibroblasts.  Normal methylation at this site is required for maintaining 
constitutive heterochromatin and overall genomic stability.  A potential 
mechanism might involve the tumor suppressor, Retinoblastoma (Rb). Rb is 
known to directly interact with the H4K20 trimethylating enzymes, Suv4-20h1 and 
Suv4-20h2. Fibroblasts that lack Rb show decreased trimethylation at H4K20, 
accompanied by striking genomic instability [175, 176].  The C-terminal region of 
Rb contains the consensus Smyd interacting motif, PXLXP.   Thus, it will be 
informative to determine if Rb is a direct methylation target of Smyd3.  If so, it will 
also be revealing to examine whether Smyd3-mediated methylation of Rb affects 
the ability of Rb to interact with the Suv-20 enzymes.  Such a finding would 
indicate that aberrant methylation of Rb by Smyd3 may be responsible for the 
decrease in global trimethylation at H4K20 in Smyd3-over-expressing fibroblasts.
 
4.5 Conclusion 
 I conclude that Smyd3 is a multiple-specificity histone methyltransferase.  
Though the over-expression of Smyd3 in NIH3T3 cells results in global reduction 
of trimethylation at H4K20, accompanied by a striking increase in cell 
proliferation, the effects of Smyd3 in other cell types may vary.  Current 
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mutational analyses of Smyd3 will undoubtedly reveal additional features that 
distinguish Smyd3 from other methyltransferases by defining its catalytic 
























Figure 4.1: Model for Smyd3 methylation of H3K4.  (a) Smyd3 is directed to 
histones via recognition of a nearby Smyd3 binding site (5'-CCCTCC-3' motif). 
Upon recruitment, Smyd3 specifically methylates H3K4 of proximal histones.  
Interaction of Smyd3 with Hsp90 is known to enhance Smyd3-mediated 
methylation of H3K4.  (b) Alternatively, recruitment of Smyd3 to its DNA binding 
element may facilitate its subsequent interaction with RNA polymerase II through 
its recruitment by the RNA helicase, HELZ.  Smyd3 could thereby progressively 
methylate H3K4 while it remains associated with the RNA polymerase II 







Figure 4.2:  Potential role of Smyd3 in tumorigenesis.  Tissue-specific genes 
are often preserved in a transcriptionally silent state by the Polycomb group 
(PcG) of proteins (top). When aberrantly expressed, Smyd3 may interact with its 
target genes, such as Nxk2.8, and out-compete the PcG-mediated silencing 
(bottom). Transcriptionally repressive methyl marks, such as H3K27, may 
thereby be altered to H3K4 by Smyd3, resulting in transcriptional activation and 
eventually, tumorigenesis.  (Adapted from Sims & Reinberg [98]) 
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Figure 4.3:  Promiscuity of Smyd3-mediated histone methylation.  (A) 
Smyd3 methylates histone H3 in addition to one or more of the diminutive 
histones (H2A, H2B, and/or H4) in an in vitro histone methyl transferase (HKMT) 
assay using mixed histones from HeLa cells as substrate. Fluorograph is shown 
in the upper panel; the 17 kD band, corresponding with Histone H3, is indicated; 
several smaller bands, presumably H2A/H2B and/or H4 are also indicated.  A 
coomassie stained SDS-PAGE gel was used to verify equal loading and is 
depicted in the lower panel.  (B)  Smyd3 methylates histones H2A, H2B, H3, and 
H4 in an in vitro HKMT assay using recombinant histones, as indicated, for 
substrate.  Fluorograph is shown and the bands corresponding with each histone 
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are indicated.  (C)  Wild type Smyd3, but not a catalytic point mutant (Y239F), 
methylate H3 and H4 in an in vitro HKMT assay using recombinant histones, as 
indicated, for substrate.  Fluorographs are shown in the upper panels; bands 
corresponding with H3 (left) and H4 (right) are indicated.  Coomassie stained 
PVDF membranes were used to verify equal loading and are depicted in the 



































Figure 4.4:  Smyd3 trimethylates H4K20.  (A) Smyd3 methylates mono-
methylated [H4(1)] and dimethylated [H4(2)] peptides in an in vitro histone 
methyltransferase (HKMT) assay using H4 peptides, representing all four states 
of methylation, as substrates.  Degree of methylation was measured by 
scintillation counting and the results are graphically displayed in counts per 
minute (CPM).  (B) Smyd3 does not monomethylate histone H4 at lysine 20 
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using recombinant histone H4 as a substrate in an in vitro HKMT assay. Western 
results, using antibodies specifically reactive with monomethylated histone H4, 
lysine 20, are shown.  (C)  Smyd3 trimethylates H4K20 in an in vitro HKMT assay 
using recombinant H4 as substrate.  Western results, using antibodies 






















Figure 4.5: Over-expression of Smyd3 in fibroblasts results in global 
reduction of trimethylation at H4K20. (A) NIH3T3 cells were transfected with 
plasmids encoding Smyd3-Myc or Smyd3 (Y239F)-Myc. Cells, transfected with 
the empty expression construct (Mock), served as control. Histones were isolated 
by acid extraction 36 hours after transfection and antibodies were used to 
determine global states of methylation.  Cells over-expressing wild type Smyd3 
exhibited a markedly decreased level of trimethylation at H4K20 as determined 
by western results, using antibodies specifically reactive with trimethylated 
histone H4K20 (upper panel).  The lower panel shows the levels of expression of 
Smyd3-Myc and Smyd3 (Y239F)-Myc at 36 hours post transfection.  (B) NIH3T3 
cells were transfected with plasmids encoding Smyd3-Myc or Smyd3 (Y239F)-
Myc. Cells, transfected with the empty expression construct (Mock), served as 
control. Histones were isolated as described above and antibodies were used to 
determine global states of methylation.  Cells over-expressing wild type Smyd3 
did not exhibit any marked difference in levels of H3K4 trimethylation (upper 
panel) or H3K9 trimethylation (lower panel), relative to Smyd3 (Y239F) or the 




Figure 4.6: Characterization of Smyd3 polyclonal antiserum.  (A) 293T cells 
were transfected with plasmids encoding Smyd1, Smyd2, and Smyd3 fusion 
proteins (as indicated).  At a dilution of 1:2000, the Smyd3 polyclonal antiserum 
was highly reactive against whole cell lysates containing Smyd3 fusion proteins 
but completely inert toward whole cell lysates containing Smyd1 or Smyd2 fusion 
proteins.  Recombinant Smyd3 was included as a positive control.  (B)  Fractions 
of the whole cell lysates described in (A) were probed with either α-Myc or α-
GAL4 antibodies to confirm the expression of each fusion protein.  (C) Spleen, 
liver, and cardiac tissues were harvested from adult mice and 100µg whole cell 
extracts were probed with Smyd3 antiserum.  Smyd3 protein was detected in 
liver and cardiac tissues but not in the spleen (left panel).  Pre-immune serum 









Figure 4.7: Smyd3 associates with N-CoR and components of the Sin3 
repression complex.  (A) The nuclear receptor co-repressor N-CoR has been 
shown to associate with the MYND domain-containing proteins ETO and BS69 in 
vitro and in vivo [107, 108].  N-CoR has also been shown to interact with the Sin3 
complex, as well as the class I and class II HDACs.  Since Smyd proteins 
associate with the Sin3 repression complex (B, [100]), we hypothesized that N-
CoR participates in the association of Smyd proteins with class I and class II 
HDACs.  293T cells were transfected with the constructs indicated and, 48 hours 
post-transfection, whole RIPA lysates were prepared. Antibodies directed against 
N-CoR were used for immunoprecipitation, followed by western analysis using 
the antibodies indicated. Smyd1B and Smyd3 are shown to associate with N-
CoR.  (B) Smyd2 and Smyd3 interact with the Sin3A but not the NuRD complex. 
293T cells were transfected with the constructs indicated and, 48 hours post 
transfection, whole RIPA lysates were prepared. Antibodies directed against 
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GAL4 were used for immunoprecipitation, followed by western analysis using the 
antibodies indicated. Smyd2 and Smyd3 associate with HDAC1 and Sin3A but 
not with the components of the NuRD complex, MBD3 or MTA2 (IgH bands are 






















5. SMYD FAMILY CHARACTERIZATION                         
5.1 Abstract 
 The SMYD Family is a group of SET and MYND domain-containing 
transcriptional regulators that function, at least partly, through histone 
modifications.  In spite of their similar architecture and enzymatic mechanisms, 
Smyd proteins induce dramatically disparate outcomes on cell proliferation.  In 
the course of studying individual Smyd family members (chapters 3 and 4), I 
have conducted various comparative analyses using the broader family.  In doing 
so, I have identified both subtle and considerable differences that may account 
for some of the unique characteristics of each family member.  Here, I present a 
compilation of those comparative studies and identify several critical factors that 
may define the unique regulatory controls imparted by individual members of the 
Smyd Family.     
 
5.2 Background 
 Smyd1, is the founding member of the Smyd family and has been most 
extensively studied.  It is driven by two discrete promoters and encodes distinct 
proteins expressed in T-lymphocytes (Smyd1C) and striated muscle (Smyd1A 
and Smyd1B) [129].  Targeted disruption of the Smyd1 gene revealed that it is 
necessary for cardiomyocyte differentiation and cardiac morphogenesis [104].  
More recently, several interaction partners have been observed for Smyd1B 
including skNAC, TRB3, MICAL, and HELZ.  The skNAC protein is a 
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transcriptional activator specific to heart and skeletal muscle  [105, 177].  TRB3, a 
regulator of mitosis [178], has been shown to enhance the transcriptional 
repression of Smyd1B that is mediated by class I HDACs.  MICAL has a 
suspected role in cytoskeletal regulation [113] and HELZ is an RNA helicase that 
also interacts with RNA polymerase II [106].  
 Smyd3 has been noted for its involvement in the proliferation of cancer 
cells [106, 152].  It is over-expressed in most hepatocellular and colorectal 
carcinomas and its transfection into NIH3T3 cells significantly augments growth 
[106].  Reciprocally, knockdown of Smyd3 with siRNA has a suppressive effect 
on the propagation of cancer cells.  Insights into potential mechanisms for 
Smyd3-mediated enhancement are provided by two important findings.  A ternary 
complex forms between Smyd3 and RNA polymerase II in which HELZ serves in 
a bridging capacity [106].  Secondly, Smyd3 functions as a transcriptional 
activator by catalyzing the methylation of H3K4 [106].   
 In addition to the findings above, several commonalities have been 
established among Smyd family members.  Smyd1B, Smyd2, and Smyd3 
interact directly with class I HDACs and this interface facilitates their potential 
role in transcriptional repression.  Similarly, all three interact with the nuclear 
receptor corepressor, N-CoR, and components of the Sin3 repression complex, 
both of which are known to recruit HDACs.  Although the presence of EBNA2 
converts Smyd1B, Smyd2, and Smyd3 into transcriptional activators, only 
Smyd1B and Smyd2 exhibit the ability to interact with EBNA2.  Likewise, Smyd3 
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is excluded from the shared abilities of Smyd1B and Smyd2 to strongly interact 
with skNAC.       
 
5.3 Results 
5.31 Smyd Family Interactions 
 In an effort to broadly shed light on the shared mechanisms of the Smyd 
family and to rapidly search for potential Smyd-methylation targets, I searched for 
proteins that interact with members of the Smyd family.  The delineation of 
Smyd-associating proteins permits valuable extrapolation of Smyd protein 
functions based on the known roles and pathways of their interacting partners.  
As numerous proteins have already been demonstrated to associate with Smyd1 
and Smyd3, I focused my efforts on establishing whether these are shared 
interactions, among the Smyd family, or if they are unique to individual Smyd 
proteins.     
 
HELZ 
 HELZ is an RNA helicase that was first demonstrated to associate with 
Smyd1B by the laboratory of our collaborator, Dr. Deepak Srivastava.  It was 
later shown to interact with Smyd3 by Hamamoto et al. [106].  In both cases, 
HELZ was pulled out of a yeast two-hybrid screen and the association was 
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subsequently validated by co-immunoprecipitation of HELZ with the respective 
Smyd protein.   
 RNA helicases function in transcription by binding to transcription factors 
and RNA polymerase II (RNAPII).  Based on this fact Hamamoto et al. predicted 
that Smyd3 may function in a transcriptional complex with RNAPII.  This 
conjecture was confirmed by showing that Smyd3 co-immunoprecipitates with 
RNAPII and served as the basis for a model where HELZ acts in a bridging 
capacity for the association between Smyd3 and RNAP II (Fig. 4.1B) [106].   
 To determine if Smyd2 can also interact with HELZ, I conducted a series 
of co-immunoprecipitation experiments.  In transient transfection experiments in 
293T cells, HELZ-Flag interacted specifically with Smyd2-Myc upon 
immunoprecipitation with anti-Myc antibodies (Fig. 5.1A).  Consistently, when cell 
extracts from 293T cells over-expressing Smyd2-Myc and HELZ-Flag were 
immunoprecipitated with anti-Flag antibodies, the immune complexes contained 
Smyd2-Myc.  Thus, I concluded that HELZ is a shared association partner 
among the Smyd family of proteins.   
 
RNA polymerase II   
 Based on the association between Smyd3 and RNAPII, documented in the 
initial characterization of Smyd3 [106], I tested the abilities of Smyd1 and Smyd2 
to associate with RNAPII.  In transient transfection experiments in HeLa cells, 
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Smyd2-Myc and Smyd3-Myc interacted specifically with endogenous RNAPII 
upon immunoprecipitation with anti-RNAPII antibodies (Fig. 5.1B).  Smyd1B also 
interacted with RNAPII, though it exhibited a much lower affinity (Fig. 5.1B).  
Thus, I concluded that RNAPII is likely a shared association partner among the 
Smyd family of proteins.     
 
MICAL 
 Molecule interacting with CasL (MICAL), a protein that has a suspected 
role in cytoskeletal regulation, was demonstrated to associate with Smyd1B by 
the laboratory of our collaborator, Dr. Deepak Srivastava [113].  Initially pulled 
out of a yeast two-hybrid screen, its association was later validated by co-
immunoprecipitation of MICAL with Smyd1B.  To test if it is a shared association 
partner among the Smyd family, I conducted a series of co-immunoprecipitations.  
In transient transfection experiments in 293T cells, MICAL-Flag interacted 
specifically with Smyd1B-Myc, but not with Smyd2-Myc or Smyd3-Myc, upon 
immunoprecipitation with anti-Myc antibodies (Fig. 5.1C).  Likewise, when cell 
extracts from 293T cells over-expressing MICAL-Flag, along with either Smyd1-
Myc, Smyd2-Myc, or Smyd3-Myc, were immunoprecipitated with anti-Flag 
antibodies, the immune complexes contained only Smyd1-Myc.  Thus, I 
concluded that MICAL is an association partner unique to Smyd1 in the Smyd 




 Mfz10 (the murine ortholog of human Frizzled2) is a member of the 
Frizzled family of proteins which have a role as cell-surface receptors for the Wnt 
family of signal ligands. Wnt signaling pathways are involved in the regulation of 
cell differentiation, proliferation and embryogenesis [179-181]. Mfz10, which is 
highly expressed during cardiac morphogenesis [182] was identified as a protein 
that associates with Smyd1B in a yeast two-hybrid screen conducted by the 
laboratory of Dr. Deepak Srivastava.  This interaction alludes to a possible 
function for Smyd1 in Wnt signaling.    
 To determine if the broader Smyd family may have a role in Wnt signaling, 
I conducted a series of co-immunoprecipitations involving individual Smyd 
proteins and Frizzled2.  Surprisingly, in transient transfection experiments in 
293T cells, Frizzled2-HA failed to interact with Smyd1B-Myc.  It also failed to 
interact with Smyd3-Myc.  It did, however, associate specifically with Smyd2-Myc 
upon immunoprecipitation with anti-Myc antibodies (Fig. 5.1D).  Similarly, when 
cell extracts from 293T cells over-expressing Frizzled2-HA, along with either 
Smyd1-Myc, Smyd2-Myc, or Smyd3-Myc, were immunoprecipitated with anti-HA 
antibodies, the immune complexes contained only Smyd2-Myc.  Personal 
communication with our collaborators in the Srivastiva Laboratory indicated that 
they too had failed to validate an association between Smyd1B and Mfz10 
(Frizzled-2) via co-immunoprecipitation.  Thus, I concluded that Frizzled-2 is an 
association partner unique to Smyd2 in the Smyd family of proteins.   
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Smyd family homo- and hetero-associations 
 Preliminary findings by Dr. Li Zhu and Dr. Robert Sims indicate that 
Smyd1 may self-associate and function as a homo-trimer (personal 
communications).  Indeed, the crystal structure of Smyd3 suggests that Smyd 
proteins could self-associate by way of their C-terminal domain without creating a 
likely source of steric hindrance near their enzymatic active sites.  Knowledge of 
homo- and/or hetero- associations among Smyd proteins would provide 
significant insight into the mechanistic basis of their functions.  Therefore, in 
order to determine if the Smyd proteins are capable of forming homo- and/or 
hetero-Smyd complexes, I conducted a series of co-immunoprecipitation 
experiments using Smyd fusion proteins.   
 In transient transfection experiments in 293T cells, Smyd1B-GAL4 
interacted specifically with Smyd1B-Myc upon immunoprecipitation with anti-Myc 
antibodies (Fig. 5.2A).  Likewise, when cell extracts from 293T cells over-
expressing Smyd1B-Myc and Smyd1B-GAL4 were immunoprecipitated with anti-
GAL4 antibodies, the immune complexes contained Smyd1B-Myc.  In both 
cases, Smyd1B-GAL4 failed to interact with a non-Smyd fusion protein (Bright-
Myc).  In parallel assays, Smyd2 and Smyd3 also demonstrated a propensity to 
self-associate (Fig. 5.2A).  Thus, I concluded that Smyd1B, Smyd2, and Smyd3 
each have the capacity to form homo-complexes.  Interestingly, each Smyd was 
also capable of co-immunoprecipitating with the other Smyd proteins (Fig. 5.2A).  
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Therefore, I additionally concluded that the Smyd proteins are competent for 
forming hetero-Smyd complexes.     
 
5.32 Smyd family methylation targets 
 As described in chapter 1.5, most histone lysine methylation is catalyzed 
by proteins containing a SET domain [27, 60].  The Smyd family comprises a 
subset of SET domain-containing proteins that have unique domain architecture.  
Specifically, this family of proteins is defined by a SET domain that is split into 
two segments by an MYND domain, followed by a cysteine-rich post SET domain 
[104]. At the onset of my research on the Smyd family, no methylation activity 
had been demonstrated for any of the Smyd proteins.  Shortly into my tenure, 
Hamamoto et al. published the initial characterization of Smyd3 which 
demonstrated for the first time that the split SET domain of the Smyd proteins is 
competent for methylation [106].  Using the histone methyltransferase protocol 
published in the Smyd3 study, I soon confirmed the enzymatic function of 
Smyd3.  In addition, I was also able to demonstrate the capacity of Smyd2 to 
dimethylate H3K36 as noted in chapter 3.33 [100].   My earliest studies also 
indicated that Smyd1B has a marginal capacity to methylate H3, relative to the 
degree of methylation catalyzed by Smyd2 (Fig. 5.3A).  The enzymatic specificity 
of Smyd1B was later more specifically defined to be H3K4 [130].  Since then, I 
have demonstrated that Smyd1B can also methylate a site on H4 that has yet to 
be delineated (Fig. 5.3B).  This finding has been independently validated by our 
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informal collaboration with Dr. Yali Dou at the University of Michigan.  Most 
recently, Dr. Li Zhu discovered the ability of Smyd1A and Smyd1B to methylate 
the muscle-specific transcription factor, skNAC (personal communication) and he 
is currently investigating the biological implications of this event.  
 
skNAC    
 skNAC, is a muscle-specific isoform of the ubiquitously expressed αNAC 
that acts as a transcriptional activator of myoglobin [177].  It has been shown to 
interact with both Smyd1A and Smyd1B [105].  For this interaction to occur, both 
the MYND and the N-SET domains of Smyd1 are necessary.  A PXLXP motif in 
skNAC is also required [105].  Smyd1 expression overlaps with that of skNAC 
during cardiac development when Smyd1-mediated methylation of skNAC is 
believed to regulate muscle-specific gene expression.  Interestingly, although 
Smyd1A and Smyd1B have both been shown to methylate skNAC in vitro, only 
Smyd1B has the ability to methylate this substrate in vivo.  
 I have shown that both Smyd2 and Smyd3 are expressed in the heart (Fig. 
3.1B).  As Smyd2 has also been noted for its ability to associate with skNAC in 
co-immunoprecipitations (Dr. Robert Sims; personal communication), it is 
reasonable to consider that skNAC may be a common methylation target among 
Smyd family members.  To determine if Smyd2 and Smyd3 can methylate 
skNAC, I conducted a series of methyltransferase assays using a fragment of 
skNAC termed E34 (5.3A).  E34 encodes amino acids 1857-2187 of skNAC and 
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was originally identified in a Smyd1B yeast two-hybrid screen [105].  E34 
methylation was tested after incubation of Smyd2 or Smyd3 with S-adenosyl-L-
[methyl-3H] methionine (SAM) and recombinant E34, as a substrate.  A band 
corresponding to 3H-labelled E34 was seen with both Smyd2 and Smyd3 in the 
fluorogram (Fig. 5.5), indicating that skNAC may be a common methylation target 
of the Smyd family.  To delineate the region of E34 that is methylated by Smyd3, 
I repeated the methyltransferase assay using a truncated fragment of skNAC.  
Although the positive control, Smyd1B, robustly methylated this fragment, there 
was no methylation in the presence of Smyd3 (Fig. 5.5).  Therefore, I concluded 
that although skNAC is likely a common methylation target of the Smyd family, 
the Smyd proteins act on distinct residues within this substrate.          
 
FKBP38    
  FKBP38 is a cytophilin involved in Hedgehog- and calcineurin/NFAT-
mediated signaling.  It has also been implicated in Bcl2-mediated apoptosis [112, 
183].   It was identified as a potential Smyd1-associating protein in a yeast two-
hybrid analysis conducted by Dr. Robert Sims (personal communication) and this 
was later validated by co-immunoprecipitation experiments.  More recently, Hui 
Nie (Tucker Laboratory) demonstrated the co-localization of Smyd1C with 
FKBP38, in vivo.  She predicted that this interaction inhibits Bcl2-mediated 
apoptosis based on phenotypes that she observed associated with the 
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conditional deletion of Smyd1 in mice.  She further proposed that this inhibition 
may be dependent upon the methylation of FKBP38 by Smyd1C.   
 To determine if FKBP38 is a potential methylation target of Smyd proteins, 
FKBP38 methylation was tested after incubation of Smyd1B, Smyd1C, Smyd2, or 
Smyd3 with S-adenosyl-L-[methyl-3H] methionine (SAM) and recombinant 
FKBP38, as a substrate.  A separate reaction including Smyd1B, SAM, and E34 
was conducted as a positive control.  A band corresponding to 3H-labelled E34 
was observed with Smyd1B in the fluorogram (Fig. 5.6A), indicating that the 
reaction conditions were adequate for lysine methylation.  However, no 
methylation was observed in any of the lanes containing FKBP38 as the 
substrate (Fig. 5.6A.  Therefore, I concluded that FKBP38 is not likely to be a 
methylation target of Smyd1B, Smyd1C, Smyd2, or Smyd3.    
 
MICAL 
 As mentioned in chapter 5.31, MICAL, a protein that has a suspected role 
in cytoskeletal regulation, was demonstrated to associate with Smyd1B by the 
laboratory of our collaborator, Dr. Deepak Srivastava [113].  Initially pulled out of 
a yeast two-hybrid screen, its association was later validated by co-
immunoprecipitation of MICAL with Smyd1B.  Recently, Hui Nie demonstrated 
that MICAL also co-immunoprecipitates with Smyd1C (personal communication) 
and she proposed that MICAL may be a methylation substrate of Smyd1.          
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 To determine if MICAL is a potential methylation target of Smyd proteins, 
MICAL methylation was tested after incubation of Smyd1B, Smyd1C, Smyd2, or 
Smyd3 with SAM and recombinant MICAL, as a substrate.  A separate reaction 
including Smyd1B, SAM, and E34 was conducted as a positive control.  A band 
corresponding to 3H-labelled E34 was observed with Smyd1B in the fluorogram 
(Fig. 5.6A), indicating that the reaction conditions were adequate for lysine 
methylation.  However, no methylation was observed in any of the lanes 
containing MICAL as the substrate (Fig. 5.6A).  Therefore, I concluded that 
MICAL is not likely to be a methylation target of Smyd1B, Smyd1C, Smyd2, or 
Smyd3.   
 
RNA polymerase II 
 I have demonstrated that Smyd1B, Smyd2, and Smyd3 associate with 
RNAPII in HeLa cells (chapter 5.31).  To determine if RNAPII is a potential 
methylation target of Smyd proteins, methylation of the C-terminal domain of 
RNAPII (RNAPII-CTD) was tested after incubation of Smyd1B, Smyd2, or Smyd3 
with SAM and recombinant RNAPII-CTD, as a substrate.  A separate reaction 
including Smyd2, SAM, and histone H3 was conducted as a positive control.  A 
band corresponding to 3H-labelled H3 was observed with Smyd2 in the 
fluorogram (Fig. 5.6B), indicating that the reaction conditions were adequate for 
lysine methylation.  However, no methylation was observed in any of the lanes 
containing RNAPII-CTD as the substrate (Fig. 5.6B).  Therefore, I concluded that 
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RNAPII-CTD is not likely to be a methylation target of Smyd1B, Smyd1C, Smyd2, 
or Smyd3.   
 
5.34 Effects of Smyd family members on cell proliferation   
 The role of Smyd3 in transcriptional regulation as a histone 
methyltransferase has been linked to its ability to augment cellular proliferation 
[106].  To investigate the relative effects that Smyd1 and Smyd2 may have on 
cell proliferation, NIH3T3 cells were transfected with either Smyd1-Myc, Smyd2-
Myc, or Smyd3-Myc.  Relative to the mock control and consistent with previous 
findings [106], over-expression of Smyd3 markedly increased cell growth (Fig. 
5.7).  Conversely, the transfection of 3T3 cells with Smyd1 or Smyd2 led to a 
decrease in their proliferation (Fig. 5.7), indicating potential roles for Smyd1 and 
Smyd2 in the maintenance of cell-cycle progression.  
 
5.4 Discussion 
  The SMYD Family is a group transcriptional regulators that 
function, in part, through histone modifications.  Despite their similar architecture 
and enzymatic mechanisms, Smyd proteins induce dramatically disparate 
outcomes on cell proliferation.  Here, I have identified both subtle and 
considerable differences that may account for some of the unique characteristics 
of each family member.  I present this data as a comparative study that highlights 
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unique factors which may help to define the unique regulatory controls imparted 
by individual members of the Smyd Family.    
 
5.41 Smyd family protein interactions    
 
Smyd role in RNAPII transcription complexes 
 A growing theme in our characterization of the Smyd family is that the 
functions of individual Smyd proteins may vary greatly, according to their 
associations with distinct complexes.  Here, I have identified two proteins that 
represent a shared association among Smyd family members.  These are the 
RNA helicase, HELZ, and RNA polymerase II.  As these two proteins are known 
to function together in transcriptional complexes, these associations link the 
methyltransferase activity of each Smyd protein with transcriptional regulation.  
This is an important finding, because there is currently much debate regarding 
how histone modifications are targeted to specific sites. These findings 
strengthen the notion that HKMTs are recruited to histones through their 
interactions with DNA-binding proteins and other constituents of transcription 
complexes.   
 There are several common forms of RNAPII involved with different stages 
of transcription [184].  These forms vary according the the phosphorylation state 
of their CTD.  When RNAPII is hypophosphorylated at its CTD, it is known to 
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interact specifically with components of the transcriptional pre-initiation complex 
[184].  Phosphorylation at RNAPII-CTD serine 5 is associated with transcriptional 
initiation and early elongation complexes [185].   Finally, RNAPII phosphorylated 
at serine 2 of its CTD is associated with progressive transcriptional elongation 
[185].  It will be informative, therefore, to determine if the Smyd proteins 
associate with a specific form of RNAPII.       
 
Smyd self-associations 
 My findings indicating that Smyd proteins can both self associate and/or 
interact with one another gives rise to many potentially convoluted pathways that 
will undoubtedly be daunting to sort out.  In the context of this thesis, I will touch 
on just one relatively simple paradigm involving the interaction of Smyd proteins 
at transcriptional complexes.  As the Smyd family is shown here to interact with 
RNAPII, I will relate the potential for Smyd proteins to associate in common 
complexes with a model illustrating their prospective involvement with different 
forms of the RNAPII transcription machinery.   
 In S. cerevisiae, the methyltransferases, SET1 and SET2, have been 
shown to interact with the initiation/early elongation and processive forms of the 
RNAPII transcription machinery, respectively.  SET1, which associates 
specifically with the serine 5-phosphorylated RNAPII complex, trimethylates 
H3K4, thereby opening the structure of chromatin and facilitating the recruitment 
of processivity factors and the 5’ mRNA capping machinery [186-188].  SET2, 
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which associates specifically with the serine 2-phosphorylated RNAPII complex, 
follows and dimethylates H3K36 along the length of the transcribed gene [186, 
188].  Dimethylated H3K36 is associated with the recruitment of the HDAC, 
Rpd3, in S. cerevisiae [127].  As histone deacetylation corresponds with 
transcriptionally inaccessible heterochromatin, a model has been proposed 
where SET1 and SET2 cooperate to achieve a rapid but short-lived 
transcriptional response [127, 188].  In S. cerevisiae, this may be linked to critical 
survival mechanisms, such as the toxic stress response, where limited 
expression of specific genes is required [189].   
 In a mammalian model, an analogous rapid transcription response 
mechanism may be ascribed to the Smyd family.  Specifically, the H3K4 activity 
of Smyd1 or Smyd3 may be associated with the serine 2-phosphorylated RNAPII 
complex, initiating transcription of specific genes.  Smyd2, which has been 
shown to associate with the human ortholog of Rpd3, HDAC1 (chapter 3.34) 
[100], could then follow, by interacting with the serine 5-phosphorylated RNAPII 
elongation complex, and methylate H3K36.  Finally, histone deacetylation by the 
associating HDAC1 would then silence transcription of the proximal genes.   
 
5.42 skNAC methylation by the Smyd family 
 In my screen of potential Smyd methylation targets, I identified skNAC as 
a common Smyd family substrate.  In preliminary assays, it appears that the site 
of skNAC methylation by individual Smyd proteins may be distinct.  Specifically, 
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Smyd1 methylates a site within the unique region of skNAC while Smyd3 targets 
a site in skNAC that is shared with the C-terminal residues of its splice variant, 
αNAC.  The αNAC protein is a transcriptional co-activator that is known to 
intereract with the c-Jun transcription factor [177, 190].  These findings suggest 
that in addition to skNAC, αNAC should be investigated for its capacity to be 
methylated by Smyd proteins.  As Smyd1 expression is restricted to heart and 
skeletal muscle, its methylation of a site that is in the unique region of skNAC is 
consistent with its expression pattern.  Similarly, since αNAC is broadly 
expressed in various tissues, its methylation by Smyd2 and/or Smyd3 would be 
in keeping with the broad expression of those Smyd enzymes. 
 
5.43 Smyd family role in methyltransferase-mediated regulation of p53  
 Smyd2 was recently demonstrated to methylate K370 of the tumor 
suppressor, p53, and this modification was shown to repress p53-mediated 
transcription [172].  Although Smyd2 has only the capacity to monomethylate 
p53, it was determined that p53 is sometimes dimethylated at K370.  As the C-
terminal region of p53 contains the consensus Smyd interacting motif, PXLXP, it 
is reasonable to speculate that another Smyd family member may be responsible 
for the dimethylation of p53.  Therefore, we are currently in the process of 




 I have identified both subtle and considerable differences that may 
account for some of the unique characteristics of each Smyd family member.  
Although they all interact with the RNAPII transcription machinery, it is likely that 
they associate with distinct forms of that complex.  Likewise, while they are each 
capable of methylating the muscle-specific transcription factor, skNAC, it appears 
that individual Smyd proteins methylate distinct residues on skNAC.  As has 
been shown with other transcription factors, such as p53, modest differences in 
points of methylation can produce drastically disparate outcomes on transcription 
[172].  The Smyd family members are also shown to have distinct effects on cell 
proliferation. These studies indicate that future research on Smyd proteins, with 
strong emphasis on the unique organismal context, will shed light onto the 
biological functions of Smyd family proteins.  Such emphasis may reveal new 
insights into the relationships between chromatin modifications and the 








Figure 5.1: Characterization of Smyd family protein interactions.  (A) Smyd2 
associates with HELZ.  HeLa cells were co-transfected with Smyd2-Myc and 
HELZ-Flag and, 48 hours post-transfection, whole RIPA lysates were prepared.  
Antibodies directed against Myc were used for immunoprecipitation, followed by 
western analysis using antibodies directed against Flag (upper panel).  Input is 
shown in lower panels.  (B) Smyd proteins associate with RNAPII.  HeLa cells 
were transfected with either Smyd1B-Myc, Smyd2-Myc, or Smyd3-Myc and 
lysates were prepared as detailed above.  Antibodies directed against Myc were 
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used for immunoprecipitation, followed by western analysis using antibodies 
directed against RNAPII (upper panel).  Input is shown in lower panel.  (C) 
Smyd1B interacts with MICAL.  293T cells were co-transfected with MICAL and 
either Smyd1B-Myc, Smyd2-Myc, or Smyd3 Myc and lysates were preparared as 
detailed above.  Antibodies directed against Myc were used for 
immunoprecipitation, followed by western analysis using antibodies directed 
against Flag (upper panel).  Input is shown in lower panel.  (D) Smyd2 interacts 
with Frizzled2.  293T cells were co-transfected with Frizzled2-HA and either 
Smyd1B-Myc, Smyd2-Myc, or Smyd3-Myc and lysates were preparared as 
detailed above.  Antibodies directed against Myc were used for 
immunoprecipitation, followed by western analysis using antibodies directed 


















Figure 5.2:  Smyd family members self-associate.  (A) Smyd family members 
form homo- and hetero-complexes.  293T cells were co-transfected with Smyd-
Myc and Smyd-GAL4 fusion proteins as indicated and, 48 hours post-
transfection, whole RIPA lysates were prepared.  Antibodies directed against 
Myc were used for immunoprecipitation, followed by western analysis using 
antibodies directed against the GAL4 epitope.  Bright-Myc, which does not 
associate with Smyd proteins, was included as a negative control.  (B) Smyd-Myc 
and Bright-Myc protein inputs are shown.  (C) Smyd-GAL4 protein inputs are 









igure 5.3:  Smyd1B has a marginal capacity to methylate histones H3 and 
H4, relative to Smyd2 and Smyd3, respectively.  (A) Smyd1B and Smyd2 
F
methylate histone H3 in an in vitro histone methyl transferase (HKMT) assay 
using 1µg recombinant H3 as substrate. The fluorograph shows a 17kD band, 
corresponding with histone H3, as indicated.  (B) Smyd1B and Smyd3 methylate 
histone H4 in an in vitro HKMT assay using 1µg recombinant H4 as substrate.  
Fluorograph is shown in the upper panel; the ~11 kD band, corresponding with 
Histone H4, is indicated; a coomassie stained membrane was used to verify 












Figure 5.4: E34 fragments of skNAC.  E34 encodes amino acids 1857-2187 of 
skNAC and was originally identified in a Smyd1B yeast two-hybrid screen [105].  
Shown here is full-length E34 (top), including a region that is shared with the C-
terminal residues of the skNAC splice variant, αNAC (green) and a region that is 
unique to skNAC (red).  Two truncations of E34 have been constructed, including 
an amino-terminal fragment (middle) that contains the region of E34 
encompassing skNAC residues 1857-1995, which are unique to skNAC, and a C-
terminal fragment (bottom) that contains the region encompassing skNAC 












Figure 5.5 Meth  members of the 
Smyd family.  Smyd1B, Smyd2, and Smyd3 methylate a fragment of skNAC in 
ylation of the E34 fragment of skNAC by
an in vitro methyltransferase assay using 1µg recombinant E34 as substrate 
(upper left).  A coomassie stained membrane was used to verify equal loading of 
E34 (lower left).  Smyd1B, but not Smyd3, methylates an E34 truncation (1857-
1995) that contains only the residues of E34 which are unique to skNAC (upper 
right).  A coomassie stained membrane was used to verify equal loading of the 








Figure 5.6: Characterization of Smyd family methylation substrates.  (A) 
Smyd1B, Smyd1C, and Smyd3 fail to methylate FKBP38 or MICAL in an in vitro 
methyltransferase assay.  A separate reaction including Smyd1B as enzyme and 
E34 as substrate was conducted as a positive control.  A band corresponding to 
3H-labelled E34 is shown in the fluorograph, indicating that the reaction 
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conditions were adequate for lysine methylation.  (B) Smyd1B, Smyd2, and 
Smyd3 fail to methylate the C-terminal domain of RNA polymerase II (RNAPII-
CTD) in an in vitro methyltransferase assay.  A separate reaction including 
Smyd2 as enzyme and histone H3, as substrate, was conducted as a positive 
control.  A band corresponding to 3H-labelled H3 is shown in the fluorograph, 






















Figure 5.7:  Effects of Smyd family members on cell proliferation. NIH3T3 cells 


























Cells transfected with the empty expression construct (Mock) served as control. All 
cells were monitored by cell counting using trypan blue exclusion. The inserts show 
the level of expression of Smyd1-Myc Smyd2-Myc and Smyd3-Myc at 24 and 144 
hours post-transfection, demonstrating similar levels of ectopically introduced 
proteins in the NIH3T3 cells. Whereas ectopically introduced Smyd3 enhanced the 
proliferation, Smyd1 and Smyd2 displayed a negative effect on the growth rate of 
NIH3T3 cells.   
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6. THE ROLE OF HSP90 IN SMYD FAMILY EXPRESSION AND CATALYSIS                        
 The molecular chaperon cilitates the maturation and/or 
activation of over 100 ‘client proteins’ involved in cell signal transduction and 
transcriptional regulation.  Largely an enigma among the families of heat shock 
proteins, it is central to processes broadly ranging from cell cycle regulation to 
cellular transformation.  Hsp90 was recently shown to interact with Smyd3, a 
methyltransferase involved in colorectal, hepatocellular, and breast cell 
carcinogenesis, and this association was demonstrated to enhance the catalytic 
activity of Smyd3.  Here I investigate the potential for Hsp90 to function broadly 
in the enhancement of SET-containing methyltransferases.  In addition, as Hsp90 
has long been noted for its capacity to impede the in vitro aggregation of a broad 
range of non-specific proteins induced to express in E. coli, I analyze the ability 
of Hsp90 to improve the otherwise marginal bacterial expression of the Smyd 
family of proteins.   
 
6.2 Background 
 Hsp90 defines a family o ones that are highly conserved 
from prokaryotes to eukaryotes [191-195].  Nonessential for normal growth in 
most bacteria, Hsp90 is abundantly expressed in higher eukaryotes where it has 





that associates with co-chaperones to catalyze the maturation and/or activation 
of over 100 substrate proteins that are known to be involved in cell regulatory 
pathways [195].    These ‘client proteins’ include protein kinases, nuclear 
hormone receptors, transcription factors, and an array of other essential proteins 
[198].  While much is known regarding the ATPase-driven conformational cycling 
of Hsp90, the precise physical effects imparted by this chaperone that serve to 
activate its substrates are still poorly understood [195].     
 
Hsp90 architecture 
 Three highly conserved domains comprise the structure of Hsp90.  These 
 A mechanistic understanding of Hsp90 was nebulous until partial 
include the N-terminal domain, responsible for ATP-binding, a proteolytically 
resistant core domain, and the C-terminal domain that facilitates 
homodimerization (Fig. 6.1A) [199, 200].  In eukaryotes, a more variable charged 
region links the N-terminal domain to the core domain.  The length and 
composition of this linker region is highly divergent among organisms [201].  As 
no atomic resolution structure for full-length Hsp90 is yet available, the most 
thorough structural analyses for Hsp90, to date, have been based on 
crystallographic studies of its individual domains.      
sequence homology was recognized between its N-terminal domain and two 
types of ATP-dependent proteins.  These included the type II topoisomerases 
and the MutL DNA mismatch repair enzymes [202].  Structural analyses of the N-
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terminal domain of Hsp90 revealed that this domain contains an ATP-binding site 
[203].  Additionally, biochemical studies suggest that transitory interactions 
between two N-terminal domains of the Hsp90 homodimer occur in an ATP-
dependent manner, and this provides the mechanistic basis for an ATPase-
driven molecular clamp [204]. Mutations in this region that impair the ability of 
Hsp90 to either bind or hydrolyze ATP  eliminate its chaperone activity [205].  
The discovery that the antibiotics, radicicol and geldanamycin, inhibit the Hsp90-
dependent activation of numerous regulatory and signal transduction proteins by 
occupying this ATP-binding site was a revelation in antitumor research [206].  
Indeed, this is the origin of almost a decade of intense efforts focusing on Hsp90 
as a therapeutic target for the treatment of cancer. 
 Biochemical and structural analyses of the core domain of Hsp90 
 The advent of the C-terminal crystal structure provided further evidence 
determined that this domain contains a catalytic loop that accepts the γ-
phosphate of ATP [207].  This led to the characterization of Hsp90 as a “split 
ATPase” [207].  Structural and mechanistic similarities shared between Hsp90 
and DNA gyrase B serve as the basis for suggesting that the core domain is also 
involved in the interface of Hsp90 with its client proteins.  Strengthening this 
position, several studies now implicate the core of Hsp90 in its interactions with 
p53, eNOS, and Akt [208-210].  
for the antiparallel dimeric architecture of Hsp90 that had been previously 
predicted by electron microscopy [211-213].  C-terminal truncations of Hsp90 
abolish its ability to hydrolyze ATP, indicating that its dimeric nature is essential 
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for its activity [204].  A highly conserved pentapeptide (MEEVD) present in the C-
terminus of eukaryotic Hsp90 is recognized by co-chaperones containing 
tetratricopeptide repeats [214-216].  Thus, the C-terminal domain is also involved 
in the formation of active Hsp90 multiprotein complexes.          
 The structural mechanism for the chaperone activity of Hsp90 has been 
 
Hsp90 co-chaperones 
 Hsp90 is not capable of autonomously functioning as a protein chaperone.  
likened to a ‘molecular clamp.’  In the absence of bound nucleotide, the N-termini 
of the Hsp90 homodimer maintain an open-state, facilitating the ‘capture’ of client 
proteins (Fig. 6.1B) [204].  Association with ATP induces modest changes to the 
conformation of Hsp90 that permit a transitory interaction between the opposing 
N-terminal domains.  This produces the closed-form of Hsp90 where clamping of 
the substrate protein occurs [204].  It is through this ATPase-driven cycle that 
Hsp90, with the assistance of several co-chaperones, induces the activation of its 
‘clientelle’ [217]. 
Instead, it serves at the core of various multiprotein complexes that incorporate 
other chaperones, such as Hsp70, and an assortment of co-chaperones [195, 
218].  The broadest class of Hsp90 co-chaperones are those containing one or 
more tetratricopeptide repeat (TPR) motifs that interact with the C-terminal 
domain of Hsp90 [219].  Beyond the conservation of their TPR motifs, these 
proteins are remarkably diverse, possessing few overlapping biochemical 
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characteristics [219].  Hop/Sti1, for example, facilitates the interaction between 
Hsp70 and Hsp90 [220], while WISp39 serves as a client protein specificity factor 
[221].  A number of TPR-containing co-chaperones even convey their own 
catalytic activities [195].  These include such enzymes as the E3/E4-ubiquitin 
ligase, CHIP [222], the protein phosphatase, PP5 [223], and several prolyl 
isomerases [224, 225].  It is known that CHIP functions in the targeting of Hsp90 
client proteins for proteasome-mediated degradation [222].  However, the 
biological functions associated with the recruitment of other enzymes to Hsp90 
chaperone complexes are still unclear.  
 Several Hsp90 co-chaperones have been shown to regulate the ATPase-
 
driven molecular clamp cycle associated with its N-terminal domain.  While 
Hop/Sti1, p23, and Cdc37 impair the progression of this cycle [215, 226, 227], 
Aha1 and Cpr6 function to enhance it [226, 228].  Because Hop/Sti1 and Cdc37 
are both involved with the recruitment of Hsp90 client proteins, their inhibition of 
the ATPase cycle is thought to permit the loading of client proteins by 
maintaining the open clamp conformation of Hsp90 [227, 229].  Cpr6 is known to 
subsequently displace Hop/Sti1 by competing for the C-terminal TPR-recognition 
motif of Hsp90, thereby permitting progression of the clamp cycle [215].  The 
Hsp90 activation potential of Aha1 is achieved through extensive associations 
along the core domain of Hsp90 that induce conformational changes within the 
Hsp90 catalytic loop.  These adjustments place the active site of the loop in 
better proximity for the acceptance of the γ-phosphate of ATP [230].   
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Hsp90 client proteins     
understanding of the effects of Hsp90 on its client 
proteins has been gleaned from its involvement with the maturation of steroid 
hormone receptors.  Steroid receptors must be maintained in a labile 
conformation that allows them to be rapidly activated in the presence of their 
cognate ligand [231].  Hop1/Sti1, by virtue of its ability to bind Hsp70 and Hsp90 
in tandem, facilitates the transfer of Hsp70-bound receptors to the open form of 
Hsp90.  The Hsp90 system then induces subtle alterations in the conformation of 
the bound steroid receptor that enhances its affinity toward its respective ligand 
[232]. 
Protein kinases comprise the most prevalent group of Hsp90 client 
proteins.  The co-chaperone Cdc37 is known to interact concurrently with protein 
kinases and Hsp90, thereby delivering client kinases to the Hsp90 chaperone 
complex [233, 234].  Bound to Hsp90, the client kinases are stabilized, and 
remain in a receptive but inactive state while awaiting appropriate signals [233].  
The details of the Hsp90-protein kinase chaperone system are still being 
characterized.        
pecific in vivo role in chaperoning authentic client proteins, 
Hsp90 has long been noted for its capacity to impede the in vitro aggregation of a 
broad range of non-specific proteins induced to express in E. coli [235].   Figure 
6.2 shows examples of proteins for which we have used strains of E. coli that 
over-express Hsp90 (Plus90αTM; Plus90βTM; Expression Technologies Inc., San 
 The most detailed 
 
 Beyond its s
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Diego, CA) to prevent aggregation during expression [100, 106, 170, 177, 236-
239].  This illustrates the structural and functional disparity among the in vitro 
clientele of Hsp90.  While the selectivity of Hsp90 for its in vivo client proteins 
points to a highly specific mechanism, the architectural variation among its 
substrates, both in vivo and in vitro, implicate a far more general mechanism.  In 
this way, Hsp90 remains an enigma among heat shock proteins.     




6.31 Protein expression systems 
Given the heightened availability of sequences for genomes from many 
organi
in d in colorectal, hepatocellular, and breast cell carcinogenesis, and this 
association was demonstrated to enhance the catalytic activity of Smyd3 [106].  
This led me to question whether Hsp90 may function more broadly in the 
enhancement of other SET-containing methyltransferases.  As Smyd3 
expression in E. coli leads to the aggregation of Smyd3 in insoluble inclusion 
bodies, I further speculated whether the co-expression of Hsp90 with Smyd3 may 
prevent such unwanted aggregation.   
sms, protein expression is increasingly important for structural and 
functional analyses of proteins. Among currently available recombinant systems 
for protein expression, E. coli is used most frequently because as a host, it is 
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relatively inexpensive, genetically well known, and can be rapidly cultivated at 
high densities [240].  However, there are countless examples of less than 
successful expression of proteins in bacterial hosts.  High level expression of 
proteins in E. coli often leads to the formation of insoluble protein aggregates, 
referred to as inclusion bodies [241].  Initial purification of inclusion bodies is 
relatively simple.  However, the agglomerated proteins must be recovered using 
strong denaturants; in turn, the correct three-dimensional conformation must be 
restored by procedures which are often time-consuming, costly, and laborious. 
Finally, obtaining the correctly folded and active enzyme is not guaranteed.  
Consequently, much effort is directed to maximize the expression of proteins in 
soluble form.   
 Although optimization of expression conditions can often reduce solubility 
 
6.32 The role of Hsp90 in Smyd family expression and catalysis 
 Among the passel of well-described and characterized chaperones, Hsp90 
displays an eclectic selectivity for the type of "client" proteins it escorts [195, 
problems, this is not always sufficient.  Currently, expression of proteins as 
fusions with affinity tags is the method of choice to achieve adequate levels of 
soluble protein [241] when the manipulation of growth conditions is not adequate.  
However, even fusion proteins can be relegated to inclusion bodies, prompting 
the more recent advent of methods that depend upon the co-expression of 
recombinant proteins with molecular chaperones [199].   
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242].  Currently, many research groups focus their efforts on defining how the 
Hsp90 chaperone machinery assists in the stabilization, assembly, or activation 
of client proteins.  At present, Hsp90 is ascribed to promote subtle changes in 
conformation and/or domain arrangement in its client proteins, facilitating 
subsequent interactions with other molecules [195, 199, 232]. 
 A far less subtle influence of Hsp90 has been observed on members of 
the Smyd protein family, reported to be involved in cell cycle regulation and the 
When expressed in a standard E. coli system, only marginal levels of 
Smyd3 or Smyd2 protein can be found in the soluble fraction (Fig. 6.2A).  As 
expect
Failure to observe the HKMT activity of Smyd3 or Smyd2, isolated from 
the insoluble fractions, prompted me to seek a method for enhanced expression 
of these proteins in the soluble fraction.  Although Hsp90α was shown to co-
biology of neoplasms [106, 236, 243].  Whereas the SET domain of Smyd3 has 
H3K4 methyltransferase (HKMT) activity, which is enhanced in the presence of 
the heat-shock protein Hsp90α [106], the SET domain of Smyd2 mediates 
H3K36-specific methylation [243]. The influence of chaperones such as Hsp90 
on the specificity and activity of HKMTs such as Smyd3 requires further 
clarification.  
ed, both of these proteins, when concentrated from the soluble fraction 
display HKMT activity (Fig. 6.2B).  However, when isolated from the insoluble 
fraction and refolded, these Smyd proteins display almost no HKMT activity (Fig. 
6.2B).   
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immun
 As discussed above, Hsp90α was reported to increase the HKMT activity 
of Smyd3 [106].  My data indicating that both Hsp90 isoforms enhance the 
solubility of Smyd3 prompted me to question whether Hsp90β could also 
oprecipitate with Smyd3 in HeLa cell lysates [106], Hsp90α has also been 
shown to form hetero-oligomers with another Hsp90 isoform, Hsp90β [244-246]. 
To determine unequivocally which Hsp90 isoform functions to chaperone Smyd3, 
I obtained E. coli strains expressing, separately, either the Hsp90α or the Hsp90β 
isoform (Plus90αTM strain and Plus90βTM strain; Expression Technologies, Inc., 
San Diego, CA) and expressed Smyd3 in each.  Contrary to my expectation, both 
isoforms, Hsp90α and Hsp90β, increased the solubility of Smyd3, indicating that 
both isoforms may function as chaperones for Smyd3 (Fig. 6.2A).  To determine 
if these strains could also enhance the soluble expression of Smyd2, it was also 
expressed in both Hsp90 strains.  Similar to Smyd3, Smyd2 expression was 
significantly enhanced in both Hsp90 strains, relative to expression achieved in a 
standard BL21 strain (Fig. 6.2A).   
enhance the enzymatic activity of Smyd3.  For these assays, Smyd3 was 
expressed in a standard BL21 E. coli strain and purified followed by a HKMT 
assay in the presence of recombinant HSP90α or Hsp90β.  Smyd3 displayed 
notably higher HKMT activity in the presence of either Hsp90α or Hsp90β (Fig. 
6.2C).  My results demonstrate that the presence of either Hsp90 isoform is 
sufficient to enhance the HKMT activity of Smyd3.  
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Although both Hsp90 isoforms augment the expression of soluble Smyd2, 
neither displayed any marked effects on the HKMT activity of Smyd2 (Fig. 6.2C).  
This suggested that Hsp90 might assist protein solubility in a more generalized 
fashion. To further define the degree of specificity toward client proteins manifest 
by the Hsp90PlusTM strains, two unrelated proteins, skNAC E34 [105] and RNA 
polymerase II carboxy terminal domain (RNA pol II CTD) [247] were individually 
expressed in each of the Hsp90 strains.   Both of these proteins exhibited 
significantly higher soluble expression in the Hsp90PlusTM strains relative to the 
standard BL21 strain (Fig. 6.2D).  
6.4 Discussion 
These data, along with the fact that Hsp90 is known to interact with over 
teins [195], indicate that the Hsp90-expressing strains may be 
effective for enhancing the expression of many distinct proteins and therefore, 
dramatically broadens the potential utility of this E. coli expression system.  I 
conclude that the Hsp90PlusTM system offers an efficient and potentially broad-
reaching approach for improving the expression of soluble and active enzymes 
for research and/or therapeutic purposes.  The increased yield of soluble enzyme 
using Hsp90 strains of E. coli provides a simple alternative to the painstaking 
task of isolating inclusion bodies and attempting to refold proteins into their 
catalytically active form.  In addition, these studies have provided new insights 




methyltransferases.  Taken together, these data should facilitate current efforts 
by other laboratories toward defining how the Hsp90 chaperone machinery 
assists in the stabilization, assembly, or activation of client proteins. 
 
Chaperoning tumorigenesis 
 The essential roles that Hsp90 fulfills in the normal physiology of healthy 
cells are even more critical for the viability of transformed cells.  Hsp90 is 
absolutely essential for the stabilization/maturation of nuclear hormone receptors, 
transcription factors, and protein kinases that are commonly misregulated during 
tumorigenesis [198].  It also serves to buffer the effects of transformation by 
preventing the aggregation of aberrantly expressed proteins, which would 
otherwise result in toxic stress signals leading to the progression of programmed 
cell death [248].  As many of the client proteins of Hsp90 are linked to growth 
signal pathways, Hsp90 is viewed as key player in the subversion of normal cells 
toward unrestrained proliferation.  Amplifying the corruptive potential of Hsp90 is 
its ability to facilitate the evolution of neoplastic clones by stabilizing many of the 
mutated proteins that are often associated with cancerous lesions, including p53, 
Bcr-Abl, and v-Src [194, 248].  For this reason, Hsp90 is thought to be especially 
crucial in the development of tumors that result from the inactivation of DNA 
repair pathways, in which there are extensive pools of variously mutated proteins 
(Fig. 6.3).    
 122
 The fact that Hsp90 enhances the catalytic activity of Smyd3, which has 
been implicated in tumorigenesis [106], further establishes a role for Hsp90 in 
chaperoning tumorigenesis.  However, the mechanism by which Hsp90 
enhances Smyd3 methyltransferase activity remains unclear.  In their original 
characterization of Smyd3, Hamamoto et al. mapped the interaction of Smyd3 
with Hsp90 to the N-terminus of Smyd3 [106].  It seems reasonable that modest 
conformational changes in Smyd3, induced by its N-terminal association with 
Hsp90, may be a mechanism for activating Smyd3.  For example, since the N-
terminal region of the Smyd3 SET domain (N-SET) is largely responsible for the 
avidity of cofactor binding [249], conformational alteration of this region may 
permit a more rapid turnover of S-adenosylmethionine, thereby enhancing the 
rate of catalysis.  Perhaps then, Hsp90 binding alleviates an intrinsic 
autoinhibition associated with the N-SET of Smyd3.  In order to address this 
question regarding the importance of the Smyd3 N-SET for methyltransferase 
activity and the potential role of Hsp90 in alleviating autoinhibition by inducing 
conformational changes in the N-SET of Smyd3, we have designed two N-
terminal truncations of Smyd3 to be tested in methyltransferase assays. 
 protein 
kinases such as ErbB-2 and v-Src [250].  It was later shown that the biological 
target of these drugs is actually Hsp90, and that their use blocks the Hsp90-
dependent activity of Raf-1, Cdk4, Src-family kinases, and many other ocogenic 
targets [248, 250].  Since then, immense progress has been made in the 
 The earliest studies highlighting the antitumor capacities of geldanamycin 
and radicicol credited their abilities to impair the activity of oncogenic
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development of pharmacological agents that act as inhibitors of Hsp90.  In 
addition to their role in cancer therapy, these drugs will undoubtedly reveal new 
insights into the involvement of Hsp90 in diverse physiological processes.   
 
6.5 Conclusion 
I conclude that the Hsp90PlusTM system offers an efficient and potentially 
broad-reaching approach for improving the expression of soluble and active 
enzym
From its crucial roles in signal transduction to transformation, Hsp90 is a 
ubiquitous molecular chaperone that influences an expansive array of cellular 
events
es for research and/or therapeutic purposes.  In addition, these studies 
have provided new insights into the effects of Hsp90 on the catalytic activity of 
two histone methyltransferases.  The prospect that Hsp90 may specifically 
interact with Smyd3 to alleviate catalytic autoinhibition mediated by the Smyd3 N-
SET region is quite novel and it is a priority of our laboratory to validate or 
disprove this idea.   
 through its broad range of protein clientele.  Hsp90 has been the focus of 
intense research for the past 20 years, resulting in the establishment of several 
overlapping paradigms stemming from the ATP-dependent chaperoning cycle of 
Hsp90.  In spite of this immense progress, many challenges remain.   For 
example, while much is known regarding the ATPase-driven conformational 
cycling of Hsp90, the precise physical effects imparted by this chaperone that 
serve to activate its substrates are still poorly understood.  In addition, the 
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currently known repertoire of Hsp90-dependent proteins is far from complete.  A 
more comprehensive listing and characterization of its clients will undoubtedly 
reveal the vast-reaching governance wielded by Hsp90 as an intermediate 
custodian of far-reaching physiological processes.  As the target for several 
promising lines of cancer therapeutics, Hsp90 is certain to remain the focus of 

















Figure 6.1:  The structure of Hsp90 and its ATP-dependent molecular 
clamp.  (a) Schematic representation of Hsp90.  The Hsp90 monomer is 
comprised of three domains: the N-terminal domain responsible for ATP-binding 
(orange), a core domain (green), and a C-terminal domain that facilitates 
homodimerization (gray).  In eukaryotes, a short charged region links the N-
terminal and core domains (black).  (b) ATP-driven molecular clamp cycle of 
Hsp90.   In the absence of bound nucleotide, the C-termini (C) of two Hsp90 
monomers interact to maintain an antiparallel dimer (left).  Concurrently, the N-
termini (N) of the Hsp90 homodimer preserve an open-state, facilitating the 
capture of client proteins (left).  On the right, association with ATP induces 
modest changes in the conformation of Hsp90 that permit a transitory interaction 
between the opposing N-terminal domains.  This produces the closed-form of 





Figure 6.2: Hsp90α and Hsp90β influence solubility and enzymatic activity 
of Smyd3. (A) Hsp90 isoform-expressing Escherichia coli (E. coli) strains 
produce higher yields of soluble Smyd3.  Wild type (lane1) and Hsp90 isoform-
expressing Escherichia coli (E. coli) strains, lanes 2 and 3, respectively, were 
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transformed with a Smyd3 expression construct.  Equal amounts (2.5 g wet cell 
paste) of cultured E. coli cells were used for isolation and purification of Smyd3.  
The migration of molecular weight markers (in kilo Daltons) is indicated. (B) 
Soluble Smyd3 is enzymatically active.  Soluble Smyd3, corresponding to lane 1 
of panel (A), was purified from cultured and transformed wild-type E. coli cells 
and subjected to an in-vitro histone methyl transferase (HKMT) assay.  Non-
soluble Smyd3 was purified and re-folded as outlined in chapter 2.  Complete 
reaction mixture without enzyme served as negative control.  Incorporation of 3H 
labeled methyl groups is presented as mean counts per minute from three 
independent experiments. (C) Hsp90 isoforms enhance the HKMT activity of 
Smyd3. Soluble Smyd3, corresponding to lane 1 of panel (A), was purified from 
cultured and transformed wild-type E. coli cells.  An in-vitro HKMT assay was 
performed using complete reaction buffer plus Hsp90α and Hsp90β, without 
enzyme, as negative control.  The incorporation of 3H labeled methyl groups is 
presented as mean counts per minute from three independent experiments. (D) 
Higher yields of soluble skNAC-E34 and RNA Polymerase II C-terminal domain 
are produced in Hsp90 isoform-expressing E. coli strains.  Wild type and Hsp90 
isoform-expressing E. coli strains were transformed with constructs, encoding 
RNA Polymerase II C-terminal domain and skNAC-E34.  Equal amounts (2.5 g 
wet cell paste) of cultured E. coli cells were used for protein purification and 


















Figure 6.3:  Role of Hsp90 in chaperoning tumorigenesis.  (a) Hsp90 
stabilizes many mutated proteins that mediate cell transformation and prevents 
e aggregation of aberrantly expressed proteins (blue), which would otherwise th
result in toxic stress signals leading to the progression of apoptosis.  (b) The 
chaperoning capacity of Hsp90 facilitates the evolution of neoplastic clones. 
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